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Over 40% of women in the United States are obese. The Strategic Plan for NIH 
Obesity Research focuses on “ways to hasten the translation of research evidence from 
discovery to intervention.” The Strategic Plan also calls on investigators to look at 
influential points in the lifespan which may affect obesity. Few interventional studies on 
obesity in women during the perimenopausal time period have been completed.  Research 
in broader populations suggests increased dairy, particularly full-fat products, may 
decrease central adiposity and improve metabolic indicators of diabetes and 
cardiovascular disease. The objective of this study was to investigate the effects of dairy 
yogurt intake in women on body composition and factors related to metabolism and 
adiposity. Women (n=59) were randomly assigned to either a full-fat yogurt, non-fat 
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yogurt, or a control group. Demographic data, health behaviors, anthropometric measures 
(Blood Pressure (BP), Body Mass Index (BMI), waist/hip circumference, body fat %), 
and metabolic indicators (glucose, insulin, cortisol, and lipid panels) were assessed. 
Forty-seven (n=47) women completed the 12-week study. There were no significant 
differences between changes in body weight, body composition, or metabolic indicators 
in the yogurt or control groups. There was a favorable decrease in systolic, F (2, 
46)=10.06, p<.001 and Diastolic F(2, 46)=6.847, p=.003, blood pressures in the full-fat 
yogurt group.  This study gives no clear support to the hypothesis that intakes of yogurt 
beneficially affects aspects of adiposity or metabolism. The positive effects on blood 
pressure with consumption of full fat yogurt suggest a possible relation to effects on the 
vasculature.
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Chapter 1 
Introduction and General Information 
Obesity Concerns 
According to the Center for Disease Control (CDC) over 70% of adult US (>20 
years old) men and women were overweight in 2013-2014; of these over 37% were obese 
(Center for Disease Control, 2016). Obesity is known to play a critical role in the 
morbidity and mortality of many cardiovascular and metabolic diseases in adults (Kaur, 
Sharma, & Singh, 2015; Kazuhiro et al., 2014; Mantatzis et al., 2014; Park et al., 2013). 
From 1980 through 2014, the number of Americans with diagnosed diabetes has 
increased fourfold (from 5.5 million to 22.0 million) (Center for Disease Control, 2015). 
Likewise, in 2014-2015, an estimated 27 million people had heart disease and 6.3 million 
incurred a cerebrovascular accident. Additionally, over 24% of the adult population had 
hypertension, and 12% were battling hyperlipidemia (Center for Disease Control, 2016). 
Women are not immune to these statistics, as 11% of the US population of adult women 
were diagnosed with diabetes between 2011 to 2014, and close to 10% of adult women 
had some form of cardiovascular disease (coronary heart disease, hypertension, stroke) in 
2014 (Center for Disease Control, 2014). 
In 2011, a taskforce for the National Institutes of Health (NIH) created the 
Strategic Plan for NIH Obesity Research (National Institutes of Health, 2011). The 
purpose of this plan was to motivate researchers to undertake projects aimed at  
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interventional discoveries in obesity treatments. Additionally, one purpose of this plan 
was to focus on particular critical time periods or points in life which may play a role in 
the development of obesity. Childhood, pregnancy, or perimenopause may be some 
examples of such time points in a women’s life that may play a role in the risk 
development.  These time points and their relationship to the increase in, or future 
development of obesity have been understudied. The goal of this program of research has 
been to help close these gaps of knowledge. 
Women’s Health/Perimenopause 
Over 40% of adult US women (>20 years old) were obese in 2013-2014 (Center 
for Disease Control, 2016). In 2010, approximately 118 million US women were over 20 
years old and potentially faced the challenges associated with increased adiposity or 
obesity (Census.gov, 2010). Signs of increased risk such as increased abdominal 
adiposity during critical time points (childhood, adolescence, perimenopause) have 
received much less research attention (Davis et al., 2012; Dasgupta et al., 2012; Jull et al., 
2014; Pimenta, Maroco, Ramos, & Leal, 2014; Sutton et al., 2010).  
Perimenopause is typically defined as the time between onset of menstrual 
irregularity and complete cessation of menstruation. Hormonal changes (namely 
declining estrogen and progesterone) during the transition may be associated with 
worsening changes in adiposity. Studies show a relationship between visceral fat 
accumulations with declining estrogen levels (Nicola et al., 2012). Of note, these changes 
of increased body fat during this time have been seen independent of the aging process 
(Datspuga et al., 2012). Inquiry into these relationships and this critical time period for 
women are still being investigated by multiple interdisciplinary groups. 
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Dairy Effects 
Emerging evidence suggests an inverse relationship between dairy consumption 
and reduced measures of adiposity in adult populations (Bhurosy & Jeewon, 2013; 
Faghih, Abadi, Hedayati & Kimiager, 2011, Jones et al., 2013; Josse, Atkinson, 
Tarnopolsky & Phillips, 2011; Holmberg & Thelin, 2013; Murphy et al., 2013; Satija et 
al., 2013; Wang et al., 2014; Zemel et al., 2005). Additionally, new findings suggest full-
fat dairy may have a more influential effect than non- or low-fat products; those who 
consume whole fat dairy may have significant lower odds of being obese (Crichton & 
Alkerwi, 2014). This is demonstrated by Danish women who consumed less butter and 
full fat dairy products in their diet and were more likely to have increased waist 
circumferences (Halkjaer, Tjonneland, Overvad, & Sorenson, 2009).   
Investigations of dairy consumption related to weight, BMI, and body 
composition with mixed results have been published over the past few years (Bhurosy & 
Jeewon, 2013; Crichton & Alkerwi, 2014; Faghih et al., 2011, Halkjaer et al., 2009; 
Holmberg & Thelin, 2013; Jones et al., 2013; Martinez et al., 2014; Murphy et al., 2013; 
Satija et al, 2013; Wang et al., 2014). Unfortunately, most research related to dairy and 
obesity measures has been prospective or observational, with very few interventional 
studies. Even fewer of these studies have focused solely on women. Of the few studies 
utilizing experimental designs, several demonstrated significant findings when using 
dairy as an intervention for reducing adiposity and improving metabolic measures in 
specific populations. Josse et al. (2011) found increased consumption of dairy foods in 
premenopausal obese women helped promote fat mass loss while on a diet and exercise 
weight loss program. Similarly, men and women who consumed yogurt during energy 
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restriction lost 81% more trunk fat than those on the control diet (Zemel, 2005). Faghih et 
al. (2011) found significant decreases in waist circumference in obese women who 
consumed high doses of dairy in their experimental study (Faghih et al., 2011). These 
findings promote the need for further inquiry into these complex dairy-adiposity 
relationships. 
Research has also identified a beneficial role of dairy on other metabolic markers 
and blood pressure (Josse et al., 2011; Nestel et al., 2013; Van Meijl & Mensink, 2013). 
Wang, Livingston, Fox, Meigs, & Jacques (2013) found yogurt consumption was 
associated with lower levels of circulating triglycerides, and glucose, lower systolic blood 
pressure, and decreased insulin resistance in American adults.  
Yogurt 
Very few studies have specifically utilized yogurt as a dietary intervention. 
However, yogurt may reduce the risk of becoming obese in adult populations (Austep, 
2014; Martinez et al., 2014; Murphy et al., 2013; Wang, Livingston, Fox, Meigs, & 
Jacques, 2013; Zemel et al., 2005.) Martinez et al. (2014) found yogurt consumption was 
inversely associated with the incidence of obesity, while Wang, Fox, Troy, Mckeown, & 
Jaques (2015) found each serving of yogurt was associated with a 6% reduced risk of 
incident hypertension. Although few experimental yogurt studies have been completed, a 
flagship research project in 2005 utilizing obese male and female adults found an 
intervention of yogurt yielded significant results for a reduction in waist circumference 
(Zemel et al., 2005). Since then further research on yogurt has been emerging in the 
literature, but further investigations of the relationship of dairy to adiposity are warranted. 
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Program of Research 
The program of research reported in this portfolio focuses on the health issues 
associated with perimenopause and examines the effectiveness of yogurt consumption on 
metabolic outcomes in women.  This program of research began with an exploration of 
the common concerns incurred during the critical time period of perimenopause.  Results 
from this review are reported in Chapter Two in the manuscript titled Current Treatment 
options for the Menopausal Transition: A Brief Review. This manuscript is currently in 
revision to resubmit to the Journal of Midwifery and Women’s Health, per request of the 
reviewers.  Findings from this review led to the identification and discussion of potential 
contributors of cardiovascular and metabolic risks in women at a certain time in the 
lifespan.   
Although emerging research on the perimenopause experience in general is 
increasing, very few researchers have investigated the complicated relationships between 
this time period, increase in adiposity, and risk factors for disease. Even fewer nutritional 
interventions have been assessed. In response to this gap in knowledge, a grant proposal 
was submitted to the Southern Nursing Research Society in spring 2015.  A copy of the 
proposal is included in Chapter Three.  While scored, but not funded, the grant 
application served as the basis for an interventional study, reported in Chapter Four.  This 
manuscript, titled Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in 
Women¸ reports the results of that study.  
Prior to study initiation, The University of Texas at Tyler’s Institutional Review 
Board (IRB) approval was secured for implementation of a randomized clinical trial to 
address this need of increased interventional studies (Appendix A).  Recruitment 
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challenges led to a subsequent increase in scope to include all adult women meeting 
inclusion criteria. The IRB approval of the modification is found in Appendix B.  
Protection of the rights of the participants in this project was upheld through a variety of 
measures implemented to ensure safety, privacy, and confidentiality for all of those 
involved.  Procedures evaluating the health status of all participants at baseline were 
documented. Safety issues related to diet, allergies, and potential drug and disease 
interactions with the intervention were also assessed. Those with disclosed dairy allergy, 
lactose intolerance, or certain enzyme deficiencies were excluded. Prior to signing the 
informed consent, full disclosure of the study’s general purpose, benefits, risks, 
participants’ rights, and responsibilities was discussed with all participants. Regulations 
for the Health Insurance Portability and Accountability Act (HIPAA) for protected health 
information was maintained at all times. Participants were notified that they could have 
terminated participation at any time for any reason without penalty. Data was stored on a 
password protected computer supplied to the researcher by the University of Texas at 
Tyler. Selection of confidential facilities when collecting sensitive data was maintained at 
all times. Also, results are being disseminated as aggregate data, with no identification of 
individual participants.  
This study’s aim was to examine the relationships between yogurt intake and 
measures of adiposity and metabolic outcomes in perimenopausal women.  Participants 
were invited to participate via a recruitment flyer (Appendix C) and letters sent to 
patients served by an obstetrics and gynecology office (Appendix D). Following 
informed consent (Appendix E) and HIPAA consent (Appendix F), participants 
completed a demographic survey (Appendix G), report of dairy consumption (Appendix 
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H), and kept a log of dairy intake (Appendices I and J).  Acceptability of the intervention 
was assessed at the end of the study (Appendix K). Results from this study are reported in 
Chapter Four. Findings from this research provide clinical data to help guide further 
inquiry of the complex relationships between nutrition, metabolism, health disease risk, 
and critical time periods in a woman’s life. A summary of this program of research, along 
with recommendations for practice and research, are discussed in Chapter Five. 
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Chapter 2  
Current Treatment options for the Menopausal Transition: A Brief Review  
Abstract 
The menopause transition is marked by a period of erratic and declining sex 
hormones which potentially result in a variety of physical and emotional concerns in 
middle aged women. Some women are asymptomatic while others report severely 
debilitating complaints. Mainstream hormonal treatment options vary in safety and 
efficacy. Millions are spent every year by perimenopausal women to treat their 
symptoms. A multitude of disciplines are eagerly seeking answers to help this population. 
Despite these efforts much still remains in question for healthcare practitioners on how to 
best handle this transitional period. Non-hormonal options are beginning to emerge with 
some support from the Food and Drug Administration. A multi-disciplinary approach, 
and further research investigation is needed. The following will review current treatment 
options for some of the most commonly reported perimenopausal symptoms. 
Keywords: menopause, perimenopause, hormone replacement, symptoms, safety
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Current Treatment options for the Menopausal Transition: A Brief Review  
The menopause transition is typically defined as the time between onset of 
menstrual irregularity and complete cessation of menstruation. There is increasing 
evidence that lifestyle, socioeconomic status, body mass index, mood, climate, and 
beliefs and attitudes towards menopause might explain the cultural variations in reported 
symptoms. Reproductive aging can span many years typically in a woman’s 40-50’s 
(O’Neil & Eden, 2012). A review of the current literature was performed utilizing the 
CINAHL Complete, Health Source, and MEDLINE databases. The following search 
terms were used: menopause, perimenopause, transition, hormone, non-hormonal, 
alternative, vasomotor, symptoms, sexuality, depression, and obesity. Only peer reviewed 
journal articles written in English were included. With the exception of the Women’s 
Health Initiative (WHI) published in 2002, all other studies reviewed were less than 5 
years old. Twelve original research studies and seven reviews were used. The following 
material will briefly review common symptoms and treatment options for perimenopause 
with discussion related to safety and efficacy.  
A Review of Common Symptoms 
Vasomotor Symptoms (VMS). The most common menopause transition 
complaints are related to thermoregulation—hot flushes/flashes and night sweats. Studies 
show 87% of women who report hot flashes experience them on a daily basis (O’Neil & 
Eden, 2012). The hot flash episodes vary in duration and may be associated with 
clamminess, anxiety, and palpitations. The median age of symptom onset is 51 and 
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typically lasts 1–6 years, but can persist longer than 15 years in some women (O’Neil & 
Eden, 2012). 
The pathophysiology of the hot flash remains unknown. Disturbed 
thermoregulation appears to be related to changes in hypothalamic activity. Reduced 
estrogen levels are thought to effect endorphins causing changes in norepinephrine and 
serotonin levels (Huntley, 2011).  The rise in core body temperature is not well 
understood, but changes in estrogen alone are not believed to account for vasomotor 
symptoms (O’Neil & Eden, 2012). Also, there appears to be a correlation with pulsations 
of luteinizing hormone and the onset of the hot flash, although a direct cause and effect 
has been disproven, so much still remains unclear on causation of poor regulation of 
temperature (O’Neil & Eden, 2012). 
Urogenital Effects and Sexual Functioning. Vaginal dryness, dyspareunia, 
reduced libido and arousal, and difficulty achieving orgasm increases through 
perimenopause and is associated with declining estrogen (O’Neil & Eden, 2012; 
Abernethy, 2013). Decreased vaginal secretions, irritation, decreased vaginal elasticity, 
decreased blood flow, and thinning vaginal walls are the result of declining circulating 
estrogen levels at menopause (Abernethy, 2013).  These events, in turn, can lead to an 
increase in vaginal and urinary infections as well as decreases in sexual satisfaction. 
Weight Gain and Increased Body Fat. Hormonal changes in the transition are 
associated with an increase in total and abdominal fat which adds risk of cardiovascular 
and metabolic disease, as well as affects quality of life. Studies show a relationship 
between visceral fat accumulations with declining estrogen levels (Nicola et al., 2012). 
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Other researchers have found perimenopause increased body fat mass and central 
adiposity, independent of age (Datspuga et al., 2012). 
Cognitive Decline. A long-standing, yet unconfirmed hypothesis is that cognitive 
difficulties occur as a result of declining estrogen. Estrogen promotes neuronal growth 
and survival and acts on the cholinergic system, which is linked to cognitive 
functioning/memory. Many report forgetfulness and concentration difficulties during 
perimenopause, but further investigation is needed.  
The Study of Women's Health across the Nation (SWAN) which was a 6-year 
epidemiologic research project, explained that perimenopausal women did not show the 
expected improvements in verbal memory and processing speed that pre- and 
postmenopausal women did (Greendale et al., 2010). In addition, they looked at whether 
depression, anxiety, sleep, and VMS affected cognitive performance/processing speed 
and found the variables did not account for the transient decrement in the learning 
observed during late perimenopause (Greendale et al., 2010).  Other investigators 
attempted to compare pre, peri, and postmenopausal women in cognitive measures and 
found postmenopausal women performed significantly worse than pre- and 
perimenopausal women on delayed verbal memory tasks, and significantly worse than 
perimenopausal women on phonemic verbal fluency tasks (Webber, Maki, & 
McDermott, 2014) demonstrating conflicting results. 
The interplay between other components such as age, mood, and sleep disturbance, make 
the “cognitive decline” variable difficult to assess. In addition, it is possible that other life 
factors during this time period may influence stress and cognitive function in ways 
independent of hormonal fluctuations.  
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Other Physical Symptoms. Most evidence suggest sleep disturbance increases 
significantly in middle-aged women. The relationship between self-reported sleep 
problems and the menopause transition have inconsistent results (O’Neil & Eden, 2012; 
Tom, Kuh, Guralnik, & Mishra, 2010). There is question if sleep disturbance is 
independent of night sweats and hot flashes. Also, a somewhat less studied symptom of 
perimenopause includes migraine headaches. Estrogen withdrawal is a recognized trigger 
and has been associated with worsening migraines in perimenopausal women 
(MacGregor, 2012). 
Emotional Symptoms. Estrogen has a role in neurotransmission involved in 
depression. Many theories suggest estrogen acts as a serotonergic agonist by increasing 
receptor binding sites, synthesis and uptake (Simon et al., 2013). Symptoms of depression 
may be attributed to factors other than just changing hormone level. Hot flashes/night 
sweats, insomnia, lifestyle, feelings for a partner, marital status, and interpersonal stress 
may significantly affect mood during the menopause transition. Cross-sectional studies 
consistently report the highest prevalence of depression occurs in women during 
reproductive years, but longitudinal studies during perimenopause have demonstrated 
conflicting results (Bromberger et al., 2011; Judd, Hickey, & Bryant, 2014; Soares & 
Frey, 2010). 
The risk of major depression may be greater for women during perimenopause 
compared to those who are pre-menopausal (Judd, Hickey, & Bryant, 2014). Mood 
changes are reported more often in Caucasian women and some concede that several 
biological and environmental factors seem to be independent predictors (Bromberger et 
al., 2011; O’Neil & Eden, 2012). In a recent literature review of 23 population based 
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studies, authors looked for evidence to support the idea that depression was the result of a 
biological response to hormone changes, but they found no proof to support this (Soares 
& Frey, 2010). 
Existing and Emerging Practice: Treatment Options 
Hormone Replacement. Hormone replacement therapy (HRT) is frequently used 
for symptoms associated with estrogen withdrawal (O’Neil & Eden, 2012). Although 
most commonly prescribed for vasomotor symptoms, new studies suggest HRT may 
partly prevent deleterious body composition changes, namely visceral fat (Nicola et al., 
2012). HRT may also be helpful for estrogen withdrawal migraines (MacGregor, 2012) 
and is effective in preventing bone loss (O’Neil & Eden, 2012).  Since bone protection 
decreases after cessation of therapy, the long-term use remains controversial (O’Neil & 
Eden, 2012).  HRT use declined some as a result of the Women’s Health Initiative (WHI) 
(Rossouw et al., 2002).  This study was intended to define risks and benefits related to the 
incidence of heart disease, breast/colorectal cancer, and fractures in postmenopausal 
women aged 50–79 years. Investigators concluded the, “overall health risks exceeded 
benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up 
among healthy postmenopausal US women” (Rossouw et al., 2002).  
 One common misconception is that WHI data should be extrapolated to the 
perimenopausal population. The potential benefits of HRT initiated during the 
perimenopause was not evaluated in the WHI as the population was mostly asymptomatic 
postmenopausal women. Hypotheses suggest endogenous sex steroids may be 
cardioprotective but the same theory using HRT has produced conflicting results. 
Findings of the WHI suggested a helpful effect in younger postmenopausal women but an 
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increased risk of heart disease/clots in older postmenopausal women (O’Neil & Eden, 
2012).  Contraindications to estrogen therapy include: history of female cancers, blood 
clots, cerebrovascular or heart disease, and liver dysfunction, among others.  
It should also be noted, “bioidentical hormones,” refers to hormones that are 
identical on a molecular level with endogenous hormones but are individually 
compounded by some pharmacies (Moriea, Silva, Santos, & Sarado, 2014) Marketing 
strategies claim these are more “natural,” and efficacious than synthetic forms, but this is 
not supported by clinical evidence and their purity and risks are not known (O’Neil & 
Eden, 2012). For now, it is widely assumed by experts that benefits and adverse effects 
are likely similar to synthetic forms of HRT, although further investigation is warranted 
(Huntley, 2011). 
Non-Hormonal Therapies and Interventions. SSRI/SNRI. Selective serotonin 
reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) 
have been marketed for off label use to treat VMS and are gaining popularity. Some 
suggest these drugs should be first line therapy for depression in perimenopause (Soares 
& Frey, 2010) while others feel adjuvant use with estradiol may be best for treatment 
of depression and VMS (Bromberger et al., 2011). Although higher doses of paroxetine 
have long been used to treat depressive and anxiety symptoms in general populations, the 
lower dose (Brisdelle) has only been approved for VMS (Simon et al., 2013). Fluoxetine 
(Prozac) and venlafaxine (Effexor) have been used for many years in perimenopausal 
women, but are not currently FDA approved. These drugs may also be helpful for treating 
migraines as well (MacGregor, 2012). 
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Anti-epileptic. Several random controlled trials show gabapentin demonstrated 
consistent and statistically significant benefits over placebo for VMS. Despite 
investigational uses for over a decade, the first largely publicized research emerged in 
2012 under the phase 3 clinical trial known as BREEZE 3. Researchers studied 600 
postmenopausal women to test extended-release gabapentin (Serada, Depomed) for 
effects on sleep and hot flashes in menopausal women (Lowry, 2012). The trial showed 
gabapentin significantly reduced the average frequency and severity of hot flashes at 4 
and 12 weeks of therapy compared to placebo (Lowry, 2012). Sleep was measured using 
both the Insomnia Severity Index (ISI) score and the Daily Sleep Interference (S/I) score. 
There were clinically meaningful reductions in the gabapentin group, compared with the 
placebo group (Simon et al., 2013). 
Unfortunately, not all experts agreed with the significance of the BREEZE study 
findings. Several members of an advisory panel for the FDA strongly opposed approval 
of the drug, suggesting the effects were only marginal and did not justify the risks. In 
2013, the FDA rejected the approval for gabapentin in menopause, claiming the drug 
failed to show superiority to the placebo. Interestingly, this same advisory panel also 
rejected their support of the low dose paroxetine (Brisdelle), but the FDA ended up still 
approving it in 2013.  
SERM. The “pink pill” or “Viagra for women” was coined in 2013 when the 
FDA approved ospemifene (Osphena), a selective estrogen receptor modulator (SERM) 
which acts similarly to estrogen on the vaginal epithelium, building vaginal wall 
thickness. SERM’s are synthetic non-steroidal agents which have varying estrogen 
agonist and antagonist activities in different tissues. Ospemifene aims to reduce 
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dyspareunia in menopausal women.  Although approved, some experts are concerned 
about long term adverse effects of ospemifene on other body systems.  
TSEC. A new class of drug combination currently under clinical trial is the tissue 
selective estrogen complexes (TSEC’s), which combine estrogen with a SERM. It is 
believed that different changes in the ER receptors may occur with different complexes 
or combinations of drugs. Therefore the drug could be utilized for either agonist or 
antagonist effects in their corresponding targeted tissues. Thus far, only bazedoxifene 
(combined with conjugated equine estrogen) has shown to be safe and effective in early 
testing. This particular combination has shown relief of menopausal hot flashes, vaginal 
atrophy, and prevention of bone loss without stimulation of the breast or uterus. Due to 
its anti-proliferative effect on the uterus, progesterone would not need to be added 
(Pinkerton & Thomas, 2014). 
Complementary and Alternative Medicine. The use of complementary or 
alternative medicine (CAM) is high in perimenopause. The concern is lack of regulation 
and little evidence to support their efficacy or safety. A systematic review of the 
prevalence of CAM usage showed the average 12-month prevalence of use was 47.7% 
(Posadzki et al., 2013). Also, 55% of women studied did not disclose their use of CAM to 
their healthcare professional. Herbal medicine, followed by soy/phytoestrogens, evening 
of primrose oil, relaxation, and yoga were the most common in the review (Posadzki et 
al., 2013). 
Phytoestrogens are plant-derived estrogens often sold over the counter with 
effects that vary according to plant species. Soy isoflavones and red clover have shown 
inconsistent results for effects on VMS (Crawford et al., 2013).  Moriea, Silva, Santos, & 
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Sardao (2014) state in a recent review that phytoestrogens “have structural similarities to 
estradiol, interacting with cell proteins and organelles, presenting several advantages and 
disadvantages versus traditional HRT in the context of menopause.”  
Black cohosh, which has no estrogenic effects, may help decrease vasomotor 
complaints by increasing dopamine and serotonin activity of the hypothalamus. However, 
in controlled trials the evidence is conflicting and there are concerns regarding liver 
toxicity (O’Neil & Eden, 2012).  Although several other complementary options have 
been investigated (vitamin E, evening of primrose, wild yam, ginseng, and others) 
research on soy, red clover, and black cohosh have been the most prominent in the 
literature. Despite occasionally producing promising results, most of these products still 
lack evidence for efficacy for menopausal symptoms. 
Calcium and Vitamin D. Both calcium and vitamin D supplement use among 
women is controversial. Necessary for the maintenance of bone health, calcium may also 
play a role in weight loss, hypertension, and a variety of cancers. The Institute of 
Medicine (2010) currently recommends 1,200 mg of calcium per day, for women 51 
years and older to reduce risk of osteoporosis. Declining estrogen is associated with 
impaired intestinal calcium absorption. Vitamin D levels and obesity have been heavily 
investigated, with more research of perimenopausal populations emerging (Truesdell, 
Shin, Liu, & Ilich, 2011). Mixed opinions exist between relationships of calcium, soy 
protein, isoflavones, bone metabolism, sarcopenia, and adiposity.  Little research has been 
performed on the relationship between vitamin D/calcium and other common symptoms 
of perimenopause. 
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Diet, Yoga, and Exercise. Diets of cyclic weight loss and gain are common in 
women and are especially harmful in perimenopause, as weight loss occurs more often 
from muscle loss. Promotion of a diet high in nutrient density and lower in energy density 
is promoted by experts (Haimov-Kochman, Constantini, Brzezinsk, & Hochner-
Celnikier,  2013) Also, mind–body, self-relaxation, and paced breathing has shown a 
reduction in severity and frequency of vasomotor symptoms in some small studies 
(O’Neil & Eden, 2012). 
No specific perimenopause exercise regimen has been recommended by experts, 
however a recent study indicated the higher frequency of exercise (aerobic and non-
aerobic), the lower severity of climacteric symptoms (Haimov-Kochman, Constantini, 
Brzezinsk, & Hochner-Celnikier, 2013). These findings contradict a recent review from 
Stojanovska, Apostolopoulous, Polman, and Borkoles (2014) who concluded there is 
“insufficient evidence demonstrating that exercise was effective in treating vasomotor 
menopausal symptoms, and, it was not clear whether exercise was more beneficial 
compared to HRT or yoga.” Furthermore, in an arm of the SWAN study, authors suggest 
acute increases in physical activity were actually associated with increased hot flashes 
without physiologic justification (Gibson, Matthews, & Thurston, 2014). 
Conclusions 
Healthcare providers of women likely feel perplexed about the current body of 
scientific literature. Menopausal symptoms are poorly understood combinations of 
genetic, psychological, and environmental factors. There is not only discrepancy between 
objectifying symptoms, but more importantly, what to actually do about them. In 
addition, some symptoms mimic other potentially age related concerns which makes 
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them difficult to assess independently. Reliable treatments have controversial safety 
profiles. Women are living longer and most will go through the menopause transition at 
some point. A team approach is best to tackle all of the health issues of this population.  
Individually tailored care plans may be needed to address symptom relief verses 
health risks. A table was developed to highlight the efficacy of currently marketed 
interventions (see Table 1). Thankfully, the interdisciplinary approach allows experts in 
the fields of endocrinology, gynecology, orthopedics, nutrition, psychiatry, and many 
others to contribute to the gaps of knowledge collectively. The WHI provided a wealth of 
information for the health of postmenopausal women. However, it also created fear of 
HRT which in turn has led to investigation of other options. Larger random controlled 
trials should be performed on the safety, efficacy, and side effects of non-hormonal 
therapies being utilized. With the widespread, and poorly regulated distribution of some 
of these substances, the potential for long term safety is concerning. 
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Table 1. Current Interventions for Perimenopausal Symptoms 
 
Level of Evidence: 
1. Evidence is sufficient to infer a causal relationship. 
2. Evidence is suggestive but not sufficient to infer a causal relationship. 
3. Evidence is inadequate to infer the presence or absence of a causal relationship 
(evidence is sparse, poor quality, conflicting). 
4. Evidence is not suggestive of a causal relationship. 
Intervention Category VMS Depression/ 
Mood 
  Sleep 
Disturbance 
Weight Gain/ 
Abdominal Fat 
  Vaginal 
Symptoms 
Reference 
        
HRT 
estrogen/ 
progesterone 
Hormonal Sufficient Sufficient Sufficient Sufficient Sufficient O’Neil 
(2012) 
Rossouw 
(2002) 
Paroxetine 
(Brisdelle) 
Venlafaxine 
(Effexor) 
SSRI/NRSI Sufficient Sufficient Inadequate Not Suggestive Not Suggestive Soares 
(2010) 
Simon 
(2013) 
Gabapentin 
(Serada, 
Depomed) 
Anti-
Epileptic 
Sufficient Not Suggestive Suggestive Not Suggestive Not Suggestive Lowry 
(2012) 
Ospemifene 
(Osphena) 
SERM Not Suggestive Not Suggestive Not Suggestive Not Suggestive Sufficient Pinkerton 
(2014) 
Soy Extracts, 
Yams Black 
Cohosh, Red 
Clover 
Herbal/ 
Isoflavone 
Inadequate Not Suggestive Suggestive Not Suggestive Not Suggestive Posadzki 
(2013) 
Crawford 
(2013) 
Moriea 
(2014) 
Calcium and 
Vitamin D 
Mineral Not Suggestive Not Suggestive Not Suggestive Suggestive Not Suggestive Truesdell 
(2011) 
Exercise and 
Yoga 
Physical Inadequate Inadequate Inadequate Sufficient Suggestive Haimov 
(2013) 
Stojanovska 
(2014) 
Gibson 
(2014) 
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Chapter 3  
Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Perimenopausal 
Women 
Southern Nursing Research Society Grant Submission Proposal 
Abstract 
Nearly 71% of U.S. women aged 40-59 are at risk for diabetes and cardiovascular 
disease due to increased obesity. The Strategic Plan for NIH Obesity Research suggests 
identifying factors unique to a specific point in the lifespan to guide obesity interventions. 
One of these critical time periods, perimenopause, has been understudied. Hot flashes and 
night sweats are familiar perimenopause complaints; symptoms such as increased central 
adiposity and decreased ability to maintain a healthy weight have received less attention. 
Research in other populations suggests increased dairy, particularly full-fat, may decrease 
central adiposity and improve metabolic indicators of diabetes and cardiovascular 
disease. 
Guided by the Integrated Theory of Health Behavior Change, a randomized 
controlled trial will determine the effect of a dietary intervention on adiposity and 
metabolic outcomes in perimenopausal women. Participants will be randomly assigned to 
either a full-fat yogurt, non-fat yogurt, or a control group. Demographic data, health 
behavior practices, anthropometric measures (BMI, waist and hip circumference), and 
metabolic indicators (glucose, lipid panels, vitamin D levels) will be assessed before and 
after the 12-week intervention. Yogurt consumption will be documented in a food diary. 
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Outcomes will be evaluated using MANOVA. A post-study survey will assess feasibility 
of the intervention. 
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Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Perimenopausal 
Women  
Objectives and Specific Aims 
The objective of this feasibility study is to improve the nutritional and metabolic 
health of perimenopausal women. Specific aims include: 
Aim 1: Determine the effect of full-fat versus non-fat yogurt consumption on metabolic 
outcomes of perimenopausal women. 
Aim 2: Determine the effect of full-fat versus non-fat yogurt consumption on adiposity 
outcomes of perimenopausal women. 
Aim 3: Determine the feasibility of yogurt consumption as a dietary intervention for 
improving metabolic and adiposity outcomes in perimenopausal women. 
Background and Significance 
According to the Center for Disease Control (CDC) nearly 71% of women aged 
40-59 were overweight or obese in 2011-2012.1 Obesity, or adiposity, is an increasing 
problem in the US (Ogden, Carroll, Kit, & Flegal, 2014).  Specifically, central adiposity 
plays a critical role in the morbidity and mortality associated with diabetes, metabolic 
syndromes, and cardio/cerebral vascular disease in adults (Mantatzis et al., 2014; Kaur, 
Sharma, & Singh, 2015; Kazuhiro et al., 2014; Park et al., 2013).  A taskforce for the 
National Institutes of Health (NIH) (2011) created the Strategic Plan for NIH Obesity 
Research. The purpose of this plan was to “serve as a guide to accelerate a broad 
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spectrum of research toward developing new and more effective approaches to address 
the tremendous burden of obesity” (NIH, 2011). One way the plan broadly proposed to 
do this was to “design and test interventions to promote healthy weight” (NIH, 2011). In 
addition, one objective of this plan emphasizes the importance of investigating factors 
related to excess weight gain during “critical periods and life events” (NIH, 2011).  The 
taskforce indicated identifying factors unique to a specific point in the lifespan could 
provide important insights for intervention development. Perimenopause, one of these 
critical time periods, has been significantly under researched. 
In 2010, approximately 23 million U.S. women between the ages of 45-54 
potentially faced the challenges associated with perimenopause (Census.gov., 2010). 
Perimenopause, the transition to menopause, is typically defined as the time between 
onset of menstrual irregularity and complete cessation of menstruation. Reproductive 
ageing typically occurs in women during their 40-50’s and is marked by a period of 
erratic and declining sex hormones resulting in a variety of physical and emotional issues. 
Although hot flashes and night sweats are two familiar complaints of perimenopause, 
other symptoms such as increased abdominal adiposity and decreased ability to maintain 
a healthy weight have received much less research attention (Datspuga et al., 2012; Davis 
et al., 2012; Jull et al., 2014; Pimenta, Maroco, Ramosm, & Leal, 2014; Sutton-Tyrell et 
al., 2010).  
Given concerns related to hormone-replacement therapy (Antoine, Ameye, 
Paesmans, & Rozenberg, 2014; Hou et al., 2013; Marjoribanks, Farquhar, Roberts, & 
Lethaby, 2012; Ohira et al., 2010; Sharpe et al., 2010) women are seeking safe, non-
hormonal interventions to combat perimenopausal symptoms. 
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One potential non-hormonal intervention for central adiposity is related to 
nutritional intake. Emerging evidence suggests an inverse relationship between dairy 
consumption and reduced measures of adiposity in other populations. Some researchers 
have focused on the effects of dairy on overall weight and BMI, (Bhurosy & Jeewon, 
2013; Jones et al., 2013; Josse, Atkinson, Tarnopolsky & Phillips, 2011), while other 
have focused more on body composition (Crichton & Alkerwi, 2014; Halkjaer, 
Tjønneland, Overvad, & Sørensen, 2009; Holmberg & Thelin, 2013; Murphy et al., 2013; 
Satija et al., 2013; Wang et al., 2014; Zemel et al., 2005). Current literature suggests full-
fat dairy may be more effective for decreasing adiposity than non or low-fat products 
(Bhurosy & Jeewon, 2013; Crichton & Alkerwi, 2014; Halkjaer et al., 2009; Holmberg & 
Thelin, 2013).  
Most research related to dairy fat has been prospective or observational, with very 
few interventional studies. Significant decreases in waist circumference in as little as 
eight weeks have been seen in obese women who consumed high doses of dairy (Faghih, 
Abadi, Hedayati, & Kimiagar, 2011). A review of current literature revealed that most 
dietary RCT’s utilizing dairy lasted 8-16 weeks in length. Yogurt may reduce the risk of 
becoming obese (Martinez-Gonzalez et al., 2014; Murphy et al., 2013; Zemel et al., 
2005). Very few experimental studies have utilized yogurt as a dietary intervention. In a 
study with 34 obese adults ages 18-50, an intervention of yogurt yielded significant 
results for waist circumference reduction (0.42 p<.005) and fat loss (0.52 p<.005).28 
Limited studies show beneficial findings when yogurt is used as an intervention for 
reducing adiposity in adults (Martinez-Gonzalez et al., 2014; Wang, Livingston, Fox, 
Meigs, & Jacques; 2013).; Zemel et al., 2005). In addition, some research on the 
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beneficial role of dairy on metabolic markers and blood pressure has been identified in 
other populations (Austep, A, 2014; Josse, Atkinson, Tarnopolsky, & Phillips, 2011; 
Nestel et al., 2013; Van Meijl & Mensink, 2013; Wang et al., 2013).  Specifically, the 
role of yogurt consumption on pertinent metabolic markers in perimenopausal women 
have not been well studied and is still unknown. The proposed study will address these 
gaps in the science.  
Research Design 
Guided by the Integrated Theory of Health Behavior Change (ITHBC) (depicted 
in Table 1 of Chapter Four), an experimental design will be utilized to address the study 
aims. The ITHBC was developed to “increase a person's ability to engage in behavior 
change to increase his/her self-management behavior” (Ryan, 2009). The ITHBC 
contributes to better understanding of health behavior by integrating knowledge and 
beliefs, self-regulation, and social facilitation. The concepts from the ITHBC were used 
to develop an intervention related to the prevention or reduction of adiposity and 
improvement of metabolic outcomes in perimenopausal women.  
Sample/Subjects 
The accessible population for this study is adult perimenopausal women living in 
North Texas. The study will take place in a private women’s health clinic in North Texas. 
The practice sees approximately 80-100 women each month for well women visits 
suggesting recruitment could be completed within three months. Since perimenopause 
relates to the beginning of hormonal changes leading up to the complete cessation of 
menstruation, the Stages of Reproductive Aging Workshop (STRAW) staging system 
(see figure 1) will be used to determine perimenopausal status (Harlow, 2012). According 
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to the STRAW definition, menstrual irregularity is described as, “the onset of menstrual 
cycle length variability with a persistent difference of 7 days or more in the length of 
consecutive cycles, with the persistence being defined as at least one recurrence within 10 
cycles of the first variable length cycle” (Harlow, 2012). 
Inclusion criteria will include: (a) perimenopausal status as defined by STRAW 
criteria (b) women who are at least 40 years old and (c) those who are able to read, speak, 
and write English. Exclusion criteria will include women with: (a) diagnosis or currently 
taking medication for diabetes or hyperlipidemia, (b) lactose intolerance, (c) allergy to 
dairy products (d) those who have had a greater than 20 pound weight change in the past 
year, or (e) women who have had a hysterectomy or oophorectomy. Women taking 
hormone replacement therapy (HRT) will be included as the effects of the nutritional 
intervention may still be effective even with low doses of HRT. 
 
Figure 1. STRAW Menopause Transition Criteria (Harlow, 2012) 
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Based on an alpha of .05, power of .80, and effect size of .35, power analysis (G-
Power 3.1) suggests a total sample size of 45 (15 per group) for repeated measures 
MANOVA will be required. Anticipated effect size (d) was calculated based on results of 
previous studies of dairy and adiposity (Crichton & Alkerwi, 2014; Josse et al., 2011; 
Wang et al., 2014; Zemel et al., 2005). To account for anticipated attrition associated 
with longitudinal studies, a total of 51 participants will be recruited. 
Measures/Instruments 
Survey Instruments. The Participant Demographic Survey (Appendix D in 
Chapter Four) will be used to collect pertinent patient demographic data. Participants will 
be providing dietary data about their use of yogurt by completing the 8-item Dairy Intake 
Questionnaire (Appendix E in Chapter Four), Daily Yogurt Form (Appendix F in Chapter 
Four), and Daily Dairy Form (Appendix G in Chapter Four). A 6-item Post Study 
Feasibility Survey (Appendix H in Chapter Four) will also be used. After development, 
the PI sent each of these instruments to content experts, colleagues, and others not 
familiar with the research to elicit feedback on the wording and face validity. The forms 
were reorganized and reworded based on feedback.  
Metabolic/Physiologic. Outcomes (Aim 1) will be measured by: Blood pressure, 
fasting serum glucose, serum insulin, fasting serum lipid panel (total cholesterol, low 
density lipoprotein [LDL], high density lipoprotein [HDL], and triglycerides), fasting 
serum vitamin D 25 OH, and free serum cortisol. Labs will be collected at the clinical site 
and will be prepared, stored, and transported according to specific local clinic and lab 
protocols. A single laboratory will be utilized for all blood analyses. Measurement of 
blood pressure will be obtained using the equipment and instruction standards described 
 32 
 
in the National Health and Nutritional Examination Survey (NHANES) Blood Pressure 
Procedures Manuals. 
Adiposity. Outcomes (Aim 2) will be measured by: body mass index (BMI), 
waist circumference (cm), hip circumference (cm), and body fat percent. Collection of 
weight and height (to calculate BMI), as well as waist and hip circumferences will be 
obtained using the equipment and instruction standards described in the National Health 
and Nutritional Examination Survey (NHANES) Anthropometry Manuals (CDC, 2009). 
The longstanding reputable history of NHANES make their manuals an appropriate 
choice for this study.  
Anthropometric measures predicted abdominal fat almost equally as well as 
Computed Tomography (CT) or Dual energy x-ray absorptiometry (DXA) scanning in 
recent study of women (Direk et al., 2013), concluding that anthropometric measures can 
be reliably utilized to derive estimates of visceral fat. Although CT and DXA are 
considered the gold standard for body fat percent measurement in clinical settings, due to 
funding limitations and access, this tool will not be utilized for this study. A professional 
grade bio-impedance scale used to determine body composition, will be used to assess 
percentage of body fat. Electrical bio-impendence monitoring has been utilized in a 
number of published studies as an alternative means to CT/DXA to assess total body fat 
percent.  
Compliance. Outcomes (Aim 3) will be assessed using the Daily Yogurt Form. 
This format will enable participants to exercise control over some of the diet decisions 
they make as well as promote behaviors of self-regulation, an integral concept in the 
ITHBC model. This form will be utilized by participants to track the number of ounces, 
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fat (grams), and brand/flavor of yogurt consumed each day. In addition, the Post Study 
Feasibility Survey will be administered to assess participants’ likelihood to continue the 
use of yogurt as part of their nutritional intake after the study is completed.  
Methods  
All participants will be interviewed in person, via phone, or email (depending on 
how they contact the PI) to assess for initial inclusion into the study. Staff at the women’s 
clinic will be instructed on how to inform prospective participants of the study and next 
steps for contacting the researcher when interested women are identified. If inclusion 
criteria are met, potential participants will be asked to meet with the PI in an initial 
session in which the purpose and procedures of the study will be disclosed. After signing 
an Institutional Review Board (IRB) approved consent form, participants will be 
randomly assigned to one of three groups (a control group, a non-fat yogurt group, or a 
full-fat yogurt group) by drawing a sealed envelope (assignment will be concealed). 
Baseline demographic surveys, anthropometric measurements, and lab work will then be 
obtained and entered into the participant’s electronic medical record. All data collection 
will be performed in an exam room to ensure privacy. Following baseline data collection, 
participants will be instructed not to make any major diet changes during the course of 
the 12-week study unless instructed to do so as indicated by the group assignment. They 
will also be asked not to change their activities or exercise regimens during this time.  
Participants will be instructed to report any new medications, changes in 
medications, or changes in health status. Participants in the full-fat and non-fat yogurt 
groups will be given a Daily Yogurt Form (Appendix F in Chapter Four) to document the 
amount and type of yogurt consumed each day. Participants in the control group will be 
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given a comparable Daily Dairy Form (Appendix G in Chapter Four) to document all 
dairy intake on a daily basis. The forms will be submitted weekly to the PI as a means to 
encourage and assess compliance with the intervention. Electronic submission via email 
will be recommended but postage paid options for regular mail will also be available. At 
the end of the 12-weeks, anthropometric measurements and lab work will be reassessed 
and again entered into the patient’s electronic medical record. In addition, the Post Study 
Feasibility Survey (Appendix H in Chapter Four) will be distributed to intervention group 
participants to obtain feedback on the intervention.  
Intervention description. The non-fat intervention group (NF) will be asked to 
consume 12 total ounces of non-fat yogurt per day for 12 weeks. The participant will be 
allowed to purchase any brand, flavor, or texture of yogurt of their choice. The 
participant will be instructed to consume commercial dairy milk yogurt (from cows) that 
cannot exceed 150 calories, 18 grams of carbs, or 0 grams of fat (per 6 ounce serving). 
They may consume the yogurt at any time each day in combination with another meal, as 
a meal replacement, or as a snack. They must record the amount in ounces and 
brand/flavor of yogurt consumed on the Daily Yogurt form (Appendix F in Chapter Four) 
each day. The participants will be asked to consume all other dairy products in the same 
amounts and frequencies as before the study and record it on the Daily Dairy Form 
(Appendix G in Chapter Four).  
The full-fat intervention group (FF) will be asked to consume 12 ounces of full fat 
yogurt per day for 12 weeks. There will not be any upper limitations on calories, carbs, or 
fat. They will be instructed to consume yogurt with at least 6 grams of fat per 6 ounce 
serving. They must record the amount, total grams of fat, and brand/flavor of yogurt 
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consumed on the Daily Yogurt Form (Appendix F in Chapter Four) each day. The 
participants will be asked to consume other dairy products in the same amounts and 
frequencies as before the study and record it on the Daily Dairy Form (Appendix G in 
Chapter Four).  
The control group (CG) will be asked to make no changes to their current dietary 
habits. They will be instructed to complete a daily dairy intake form. Though this 
heightens awareness of consuming dairy products, the emphasis is not on yogurt. The 
form will serve as a means to assess typical yogurt intake within the sample.   
Data Collection 
Baseline demographic survey and dairy intake form, anthropometric measures, 
and blood draws will be performed by the PI at baseline. Yogurt (intervention groups) 
and dairy (control group) diaries will be collected every two weeks for 12 weeks. 
Participants will be asked to submit the diaries either electronically to an email address 
dedicated to the study or by mail using a postage paid envelope provided by the study. 
Anthropometric measures and blood samples will also be collected by the PI at the 
conclusion of the study, along with the post yogurt study survey. All survey data 
completed on paper will be stored in a locked file in a locked office. Anthropometric 
measures and lab reports will be recorded in a secure electronic medical record system 
which is password protected. All study data will be transcribed into a password protected 
Statistical Program for the Social Sciences (SPSS version 20.0) database for analysis. 
Double entry will be utilized to assure error free data.  
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Plans for Statistical Analysis 
Data will be assessed for accuracy, outliers, and missing responses prior to 
conducting analysis. Discrete variables will be examined for accuracy. Continuous 
variable means and standard deviations will be examined for credibility and to assess for 
outliers. Descriptive statistics will be calculated for each variable. For continuous 
variables, range, mean, median, and standard deviation will be used. For categorical 
variables, mean, frequency, and contingency tables will be used. Chi-square tests (for 
nominal level data) and ANOVA (for continuous level data) will be used to compare the 
distribution of the demographics of the three groups at baseline. Multivariate analysis of 
variance (MANOVA) will be used to analyze the effect of yogurt consumption on 
adiposity (AIM 1) and metabolic indicators (AIM 2) among groups. If significant 
differences are noted, post hoc analyses will be conducted to determine where the 
differences lie. 
Feasibility (AIM 3) will be assessed via time required for recruitment, attrition 
rate, Daily Yogurt/Dairy Intake form completion, and responses to the Post Study 
Feasibility Survey. Recruitment will be calculated by determining the length (in business 
days) it takes to obtain the 25th and 51st participant from the start of recruitment. 
Intervention items will be reviewed by the research team to identify issues that affected 
the consumption of yogurt in perimenopausal women. The PI, recruitment assistants, and 
clinic staff will discuss any challenges they faced during recruitment to identify measures 
to improve the process for future study. 
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Limitations and Potential Difficulties 
Limitations. As with any longitudinal study, attrition could be a limitation.  
Oversampling will be done to allow for potential loss of participants. Utilizing one local 
clinic for assessment completion could be a limitation. Other surrounding clinics in 
Northeast Texas may be utilized if additional recruitment of participants is needed. 
Flyers, will be posted in numerous public and private settings with potential sources of 
perimenopausal-aged women (e.g. local healthcare establishments, shopping venues, 
beauty salons, churches). Woman in the intervention groups may become tired of 
consuming 12 ounces of yogurt every day. To address this limitation, no restrictions will 
be made for the brand, flavor, or texture of yogurt chosen. No constraints on the time of 
day they will eat yogurt will be mandated, which will aid in flexibility of schedule. The 
potential for confounding variables, despite exclusion criteria, cannot be entirely 
controlled. Since standardization of only a few (not all) nutritional parameters will be 
performed, other nutritional co-variables will still exist.  Exercise or energy expenditure 
will not be measured or controlled. Subjects will be asked not to make any other changes 
in exercise or diet during the study. Although this opens the possibility of confounding 
variables, this approach also reflects a real-world approach and will help determine if 
yogurt consumption is feasible without placing additional demands or restrictions on 
participants. Maintaining previous behaviors mitigates the source or impact of extraneous 
behaviors since the participants serve as their own controls. 
 The possibility of varying degree of ovarian function within the perimenopausal 
status could be a confounding factor. Assessing menstrual health through STRAW 
criteria will help provide some commonality for those in perimenopausal states. Some 
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variability and human error is possible when obtaining anthropometric measurements. 
Body composition differences, racial and ethnic differences, and clinician technique, can 
all lead to discrepancy. Body composition differences and racial and ethnic differences 
are addressed in baseline data. Clinician technique is addressed by using the same person, 
equipment and lab to collect and analyze data will help reduce this limitation. The self-
reported nature of food consumption is also a limitation. Participants may feel 
inconvenienced by having to write in a daily log. This may lead to falsification or 
inaccurate recall of consumption. Therefore, a simplified, user friendly form was created 
to help compliance.  
Potential Difficulties. One anticipated challenge is recruitment of an adequate 
number of participants. To make study participation more appealing, women are being 
offered free assessments of body composition and several metabolic indicators at two 
time points. The major challenge in conducting this type of research is the fiscal 
resources necessary to conduct the study. Women cannot be asked to pay out of pocket to 
cover blood work; providers cannot be expected to provide services for free. In this study, 
the PI, who is a women’s health nurse practitioner, will provide the assessments at no 
cost. The lab that supports the PI’s practice has negotiated the lowest cost possible to 
provide lab services and still cover expenses.  
Protection of Human Subjects 
Protection of the rights of the participants in this project will be upheld through a 
variety of measures implemented to ensure safety, privacy, and confidentiality for all of 
those involved. All procedures will be evaluated and approved by the Institutional 
Review Board at the University of Texas at Tyler. Procedures evaluating the health status 
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of all subjects at baseline will be documented. Safety issues related to diet, allergies, and 
potential drug and disease interactions with the intervention will also be assessed. For 
example, those with disclosed dairy allergy, lactose intolerance, or certain enzyme 
deficiencies would be excluded. Prior to signing the informed consent, full disclosure of 
the study’s general purpose, benefits, risks, participants’ rights, and responsibilities will 
be discussed with all participants. Regulations for the Health Insurance Portability and 
Accountability Act (HIPAA) for protected health information (PHI) will be maintained at 
all times. HIPAA consents will be obtained. Participants will be notified that they may 
terminate participation at any time for any reason without penalty. Selection of 
facilities/rooms/privacy interventions when collecting sensitive data (such as 
anthropometric measurements) will be maintained at all times. Secure record keeping of 
data and storage with password access will also be utilized during the study. Results will 
be disseminated as aggregate data, with no identification of individual participants. 
Data Safety and Monitoring Plan 
Contact information of the research team will be provided to all study participants 
at the beginning of the research project. They will be instructed to notify the researcher of 
any emergencies, unforeseen events, or general concerns that arise as a result of 
participating in this study. If an event is reported, the researcher will promptly notify her 
adviser, and co-investigators for guidance and documentation of the event in an adverse 
event log. A written notification will be submitted to the IRB within 24 hours of the 
reported incident.
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Appendix A: Budget Sheet 
 
Anticipated Expenditures 
Laboratory Fees $4284.00 
$42 @ baseline x 51 participants=$2142  
$42 @ completion X 51 participants=$2142  
Bio-impedance Body Composition Scale $2595.00* 
Palm Aneroid Sphygmomanometer $50.00 
Printing Costs  
9 pages x $.10 x 51 (all participants)=$45.90 
1 page x $.10 x 34 (Intervention participants) 
$3.40 
$49.30 
Postage for return of diaries. 
$0.49x12x51=$299.88 
 
$299.88 
TOTAL $7278.18 
Total Requested from SNRS $7078.26 – 2595 = $4683.18 
 
Budget Justifications: 
Laboratory Fees: Discounted negotiated (at cost) pricing from the lab utilized at the local OB-
GYN clinic are as followed: Cortisol ($13.29), Vitamin D, 25 OH ($19.00), Glucose ($1.70), 
Insulin ($7.00), Lipid Panel ($2.15). 
*Bioimpedance Body Composition Scale: Professional Grade Bio-impedance Scales vary in 
pricing with most quality models falling in the $2,000-$6000 range. The price listed here is for a 
Tanita™ TBF-410 Body Composition Analyzer that includes Tanita HealthWare™ software. The 
Tanita HealthWare™ provides a bridge to most electronic medical record software packages, 
which sends the measurements directly to the participants EMR reducing the chance of 
transcription error. The Tanita™ TBF-410GS Body Composition Analyzer calculates body fat 
percent in less than ten seconds and has a column-mounted display to decrease unintentional 
damage of the equipment. Price listed is based on current listing from the Tanita™ website. The 
The Bodystat™ Quadscan 4000 with Microsoft™ software is also being considered and costs 
around $5700. This bio-impedance scale has been utilized by numerous healthcare companies and 
researchers in a variety of peer reviewed published studies with excellent reputation. 
*Recognizing the cost of either of these scales exceeds that permitted by the grant, additional 
funding will be sought to cover the cost of this item. 
Sphygmomanometer: Equipment currently utilized at the OB-GYN office will be assessed prior 
to data collection to determine that it is professional grade, correctly calibrated, and working 
properly. If it is not, a sphygmomanometer will need to be purchased to record accurate blood 
pressure readings. 
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Appendix A: Budget Sheet Continued 
 
Printing Costs: Participant surveys and diaries will be completed on paper. These will be printed 
at a local print shop such as Kinko’s™ (or similar) for efficiency and pricing. 
Postage Costs: Participant Yogurt/Dairy Intake diaries will be returned via postage paid envelope 
every two weeks for participants unable or choose not to utilize email correspondence. This 
would include 12 postage paid envelopes per participant (51) x $0.49 per stamp, totaling $299.88. 
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Chapter 4 
Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Women 
Abstract 
Over 40% of adult women in the United States are obese. The Strategic Plan for 
NIH Obesity Research focuses on ways to improve and expedite the ways at which 
research discovery develops into clinical intervention. Research in other populations 
suggests increased dairy, particularly full-fat, may decrease central adiposity and improve 
metabolic indicators of diabetes and cardiovascular disease. The objective of this study 
was to investigate the effects of dairy yogurt intake on body composition and factors 
related to metabolism and adiposity in women. Women (n=59) were randomly assigned 
to either a full-fat yogurt, non-fat yogurt, or a control group. The full-fat and non-fat 
groups were instructed to consume 2 servings of yogurt daily. The control group 
maintained their habitual diet. Clinical measurements were completed on admission to 
the study and after 12 weeks. Demographic data, health behaviors, anthropometric 
measures (BMI, waist/hip circumference, body fat %), and metabolic indicators (glucose, 
insulin, cortisol, and lipid panels) were assessed.  Forty-seven (n=47) women completed 
the 12 week study. There were no significant differences between changes in body 
weight, composition, or metabolic indicators across time within the yogurt or control 
groups. There was a modest favorable decrease in systolic (p<.001) and diastolic 
(p<.003) blood pressure in the full-fat yogurt group. This study gives no clear support to 
they hypothesis that a diet with increased intake of yogurt beneficially affects aspects of 
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the adiposity or metabolism. The positive effects on blood pressure with consumption of 
full fat yogurt suggest a possible relationship to effects on the vasculature should be 
further explored.
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Effect of Dairy Consumption on Adiposity and Metabolic Outcomes in Women 
According to the Center for Disease Control (CDC) over 40% of adult US women 
(>20 years old) were obese in 2013-2014 (Center for Disease Control, 2016). Obesity, or 
adiposity, and specifically increased central adiposity, play a critical role in morbidity 
and mortality associated with diabetes, metabolic syndromes, and cardio/cerebral 
vascular disease in adults (Kaur, Sharma, & Singh, 2015; Kazuhiro et al., 2014; 
Mantatzis et al., 2014; Park et al., 2013). In 2011, a taskforce for the National Institutes 
of Health (NIH) created the Strategic Plan for NIH Obesity Research “serve as a guide to 
accelerate a broad spectrum of research toward developing new and more effective 
approaches to address the tremendous burden of obesity” (National Institutes of Health, 
2011, p. 7). One way the plan broadly proposed to do this was to “design and test 
interventions to promote healthy weight” (National Institutes of Health, 2011, p. 15). In 
addition, one objective of this plan emphasizes the importance of investigating factors 
related to excess weight gain during “critical periods and life events” (National Institutes 
of Health, 2011, p. 21).  The taskforce indicated identifying factors unique to a specific 
point in the lifespan that could provide important insights for intervention development. 
Adolescence, young adulthood, pregnancy, perimenopause, and post menopause are 
potential critical periods that have been understudied. 
In 2010, approximately 118 million US women were over 20 years of age and 
potentially faced the challenges associated with increased adiposity or obesity
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(Census.gov, 2010). Symptoms such as increased abdominal adiposity and decreased 
ability to maintain a healthy weight during specific critical life events such as 
perimenopause have received much less research attention (Davis et al., 2012; Dasgupta 
et al., 2012; Jull et al., 2014; Pimenta, Maroco, Ramos, & Leal, 2014; Sutton et al., 
2010). Additional investigation of such critical time periods and their influence on 
adiposity are needed. Furthermore, interventional research to address the increasing 
adiposity at all ages is also warranted.  
Review of the Literature 
The retrieved body of evidence suggests an inverse relationship between dairy 
consumption and reduced measures of adiposity in adults (Bhurosy & Jeewon, 2013; 
Faghih, Abadi, Hedayati, & Kimiager, 2011, Jones et al., 2013; Josse, Atkinson, 
Tarnopolsky, & Phillips, 2011; Holmberg & Thelin, 2013; Murphy et al., 2013; Satija et 
al., 2013; Wang et al., 2014; Zemel et al., 2005). Current literature also suggests full-fat 
dairy may be more effective for decreasing adiposity in adults than non- or low-fat 
products. In the Observation of Cardiovascular Risk Factors in Luxembourg survey, data 
were analyzed from 1352 men and women and researchers found those consuming the 
highest amounts of whole-fat dairy intakes (milk, cheese, yogurt) had significantly lower 
odds of being obese (Crichton & Alkerwi, 2014). Also in another study, Danish women 
who consumed less butter and full fat dairy products in their diet were found to be more 
likely to have increased waist circumferences (Halkjaer, Tjonneland, Overvad, & 
Sorenson, 2009).  Outcomes of studies on the effects of dairy products have varied from 
overall weight, BMI (Bhurosy & Jeewon, 2013; Martinez et al., 2014), and body 
composition (Crichton & Alkerwi, 2014; Faghih et al., 2011, Halkjaer et al., 2009; 
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Holmberg & Thelin, 2013; Jones et al., 2013; Murphy et al., 2013; Satija et al., 2013; 
Wang et al., 2014).  
Unfortunately, most research related to dairy and obesity measures has been 
prospective or observational, with very few interventional studies. Even less of these 
studies have focused solely on women. Of the few studies found utilizing experimental 
designs, several demonstrated significant findings when using dairy as an intervention for 
reducing adiposity and improving metabolic measures. Josse et al. (2011) found 
increased consumption of dairy foods in premenopausal obese women helped promote fat 
mass loss for those on a diet and exercise weight loss program. Also, men and women 
who consume yogurt during energy restriction lost 81% more trunk fat than those on the 
control diet (Zemel, 2005). Faghih et al. (2011) found significant decreases in waist 
circumference in as little as eight weeks in obese women who consumed high doses of 
dairy in their experimental study.  
Research has also identified a beneficial role of dairy on metabolic markers and 
blood pressure (Josse et al., 2011; Nestel et al., 2013; Van Meijl & Mensink, 2013). 
Wang et al. (2013) found yogurt consumption was associated with lower levels of 
circulating triglycerides, glucose, and lower systolic blood pressure and insulin resistance 
in American adults participating in the Framingham Heart Study Offspring (1998-2001) 
and Third Generation cohorts (2002-2005).  
Few studies have specifically utilized yogurt as a dietary intervention, however, 
this specific dietary choice may reduce the risk of becoming obese in adult populations 
(Austep, 2014; Martinez et al., 2014; Murphy et al., 2013; Wang, Livingston, Fox, Meigs, 
& Jacques, 2013; Zemel et al., 2005.) Martinez et al. (2014) focused on yogurt and found 
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consumption was inversely associated with the incidence of obesity in a group of 8,516 
Mediterranean men and women.  In a seminal study that utilized yogurt as an intervention 
for adiposity, Zemel et al. (2005) found obese male and female adults ages 18-50, who 
consumed an intervention of yogurt yielded significant results for waist circumference 
reduction (Zemel et al., 2005). The Zemel study provided a new avenue for researchers 
hoping to find an effective intervention for the obesity epidemic. The role of yogurt 
consumption on adiposity and other pertinent metabolic markers in women has not been 
well studied and is still unknown. The following study sought to address these gaps in the 
science.  
Theoretical Framework 
The Integrated Theory of Health Behavior Change (ITHBC, Figure 1) was 
developed to “increase a person's ability to engage in behavior change to increase his/her 
self-management behavior” (Ryan, 2009). Subjects who engage in these self-
management behaviors are expected to achieve the initial (proximal) short term outcome 
which in turn leads to the longer (distal) outcome of an overall improved health status. 
Individualized interventions are used to increase knowledge and beliefs, facilitate social 
support, and improve self-regulation skills and abilities. Ryan (2009) advocated that 
using a theoretical framework would help advance practice nurses’ focus on assessments, 
utilized evidence based interventions, and improve patient outcomes. Using the ITHBC is 
expected to help improve interdisciplinary communication and foster holistic 
comprehensive care (Ryan, 2009). No known dietary studies utilizing dairy in women 
have previously applied the ITHBC as the theoretical framework guiding their research. 
Ryan (2009) proposes that knowledge and beliefs and social facilitations in the 
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ITHBC contribute to a person’s self-regulation skill and ability, which in turn lead to 
achievement of the health outcomes. The ITHBC was used to guide a yogurt intervention 
in women (Figure 2).  
 
Figure 2. Integrated Theory of Health Behavior Change for a Yogurt Intervention 
(Adapted from Ryan, 2009) 
Knowledge and beliefs includes condition specific and personal perception 
factors. For use in women, this included women’s knowledge about dairy consumption as 
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well their perception that dairy could help them lose weight, decrease abdominal fat, and 
improve their metabolic health (such as BP and cholesterol levels.)  
Social facilitation for this study was support from other women, family, and/or 
friends. Other social facilitation came from healthcare providers who taught the 
participant about the yogurt intervention. Access to yogurt (availability, ease of purchase, 
financial burden) also were components of the ITHBC’s social facilitation category.  
Self-regulation and ability in the ITHBC framework are further broken down into 
goals, monitoring, decision making, planning, and evaluation/emotional response. For 
this study, goals were related to decrease measures of adiposity (such as waist 
circumference/BMI) and improving metabolic outcomes (such as increase HDL levels). 
Choosing what brand, flavor, and time of day to consume the yogurt was part of the 
decision making category of self-regulation. Planning the consumption of yogurt was 
influenced by work, home life, vacations, and typical eating schedules. Although 
typically an inexpensive food, cost of yogurt also played a role in planning and grocery 
budgeting. Evaluation and emotional response were completed at the end of the study 
when the participants reflected on whether they like the yogurt, if they were able to eat it 
twice daily, if they felt they could continue eating it routinely after the study, and if they 
felt it was helping them lose weight and improve their health. 
The outcomes from the yogurt intervention were measured by engagement in self-
management behaviors during the study. The proximal outcome was that women would 
consume 12 ounces of yogurt daily. This in turn was expected to lead to the distal 
outcome of improvement in health status by reducing measures of adiposity and 
improving metabolic outcomes through serum laboratory results. 
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Conceptual and Operational Definitions 
Several variables were utilized to help measure the research hypotheses/question 
for this study. The following table (Table 2) outlines the conceptual and operational 
definitions of the utilized variables in this study. 
Table 2. Conceptual and Operational Definitions 
Variable Conceptual Definition Operational 
Non-Fat 
Yogurt 
A food produced by bacterial (“yogurt 
cultures”) fermentation of milk. 
Fermentation of lactose creates lactic 
acid, which acts on milk protein to give 
yogurt its texture and its taste. The fat 
content of milk is the proportion of 
milk, by weight. Non-fat yogurt has 
had the butterfat removed. According to 
the USDA regulations skim milk or 
“nonfat" milk, can be labeled “fat free” 
if it contains less than ½ gram of fat per 
serving. 
Any brand/flavor/texture of 
yogurt made from dairy 
cow’s milk which 
contained 0 grams of total 
fat were to be used in this 
study. 
Full-Fat 
Yogurt 
 
A food produced by bacterial (“yogurt 
cultures”) fermentation of milk. 
Fermentation of lactose creates lactic 
acid, which acts on milk protein to give 
yogurt its texture and its taste. The fat 
content of milk is the proportion of 
milk by weight. Typically in the United 
States, “whole milk,” or full fat 
products contains at least 3.25% 
butterfat. 
Any brand/flavor/texture of 
yogurt made from dairy 
cow’s milk which contains 
at least 6 grams of total fat 
were to be used in this 
study. 
Body Mass 
Index (BMI) 
The body mass index (BMI) is a 
measure of relative weight based on an 
individual's mass and height.  
BMI was calculated by 
dividing the subject’s 
weight in pounds (lbs.) by 
height in inches (in) 
squared and multiplying by 
a conversion factor of 703 
(to convert from metric to 
standard measurement. 
Waist 
Circumference 
Numerical measurement of waist often 
measured in cm using an 
anthropometric (soft flexible) tape 
measure. A high waist circumference is 
associated with an increased risk for 
type 2 diabetes, dyslipidemia, 
Anthropometric tape was 
used to measure half way 
between the inferior 
margin of the last rib and 
the crest of the ilium in the 
mid-axillary plane. 
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hypertension, and cardiovascular 
disease. Waist circumference can 
provide an estimate of abdominal fat.  
Centimeters were utilized. 
Detailed procedure steps 
described in NHANES 
Anthropometric Procedure 
Manual (CDC, 20011). 
Hip 
Circumference 
Hip circumference is a measurement of 
a person’s hip size in centimeters (cm) 
using anthropometric tape. Hip 
circumference is a measurement of 
obesity. People with "apple-shaped" 
bodies (with more weight around the 
waist) face more health risks than those 
with "pear-shaped" bodies who carry 
more weight around the hips. 
Anthropometric tape was 
used to measure the 
circumference of the hips 
at the widest part of the 
buttocks. Centimeters were 
utilized. Detailed 
procedure steps described 
in NHANES 
Anthropometric Procedure 
Manual (CDC, 20011). 
Fat Mass %: The percentage of a person’s body that 
is not composed of fluids, muscle, 
bone, and vital organs. 
Number in percent (%) 
calculated via bio-
impedance weight scale.  
Blood Pressure The pressure exerted by circulating 
blood upon the walls of blood vessels. 
"Blood pressure" usually refers to the 
arterial pressure of the systemic 
circulation, and is often measured in the 
upper arm. Blood pressure is expressed 
in terms of the systolic pressure over 
diastolic pressure and is measured in 
millimeters of mercury (mm Hg). 
Normal resting blood pressure for an 
adult is approximately 120/80 mm Hg. 
Same as conceptual 
definition. Specific 
procedure described in 
NHANES BP Procedure 
Manual (CDC, 2009). 
Insulin A peptide hormone produced by beta 
cells in the pancreas. It regulates the 
metabolism of carbohydrates and fats. 
It promotes the absorption of glucose 
from the blood to skeletal muscles and 
fat tissue. 
Level of (8+ hour) fasting 
insulin obtained from 
serum blood draw. 
 
 
Glucose A monosaccharide found in plants that 
is absorbed directly into the 
bloodstream during digestion and aids 
in cellular function. 
Level of (8+ hour) fasting 
glucose obtained from 
serum blood draw. 
Cortisol A glucocorticoid steroid hormone, 
produced in adrenal glands. It is 
released in response to stress and low 
blood glucose levels. Cortisol increases 
blood sugar, suppresses the immune 
system, and helps with metabolism of 
fat, protein, and carbohydrate. 
Level of (8+ hour) fasting 
cortisol will be obtained 
from free cortisol levels 
drawn from serum blood. 
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Total 
Cholesterol 
A lipid molecule that is biosynthesized 
by all cells since it is a component of 
cell membranes. Cholesterol is also a 
precursor for the biosynthesis of steroid 
hormones, bile acids, and vitamin D. 
All foods containing animal fat contain 
cholesterol. 
Level of (8+ hour) fasting 
total cholesterol obtained 
from serum blood draw. 
 
 
Low Density 
Lipoprotein 
(LDL ) 
Cholesterol 
LDL is one of the five major groups of 
lipoproteins whose particles pose a risk 
for cardiovascular disease when they 
invade the endothelium and become 
oxidized. Lipoproteins are complex 
particles composed of multiple proteins 
which transport all lipids. They are 
typically composed of 80-100 
proteins/particles. LDL particles are 
often called “bad cholesterol” because 
they can transport their content of fat 
molecules into artery walls, attract 
macrophages, and high levels are 
associated and an increased risk of 
atherosclerosis.  
Level of (8+ hour) fasting 
LDL cholesterol obtained 
from serum blood draw. 
 
 
High Density 
Lipoprotein 
(HDL) 
Cholesterol 
HDL is one of the five major groups of 
lipoproteins. Lipoproteins are complex 
particles composed of multiple proteins 
which transport all lipids. They are 
typically composed of 80-100 
proteins/particles. Unlike the larger 
lipoprotein particles which deliver fat 
molecules to cells, HDL particles 
remove cholesterol molecules from the 
blood decreasing their risk of 
atherosclerosis.  
Level of (8+ hour) fasting 
HDL cholesterol obtained 
from serum blood draw. 
 
 
Triglycerides Triglycerides are esters created from 
glycerol and fatty acids that act as a 
blood lipid to aid in transfer adipose fat 
and blood glucose from the liver. 
Level of (8+ hour) fasting 
Triglycerides obtained 
from serum blood draw. 
 
Research Hypotheses and Question 
 
The objective of this study was to improve the nutritional and metabolic health of 
women. Specific research hypotheses (Ha) and the research question (RQ) were as 
follows:  
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Ha1: Yogurt consumption will have a beneficial effect on metabolic outcomes of 
women.  
Ha1a: This effect will be greater in those consuming full fat products.  
Ha2: Yogurt consumption will have a beneficial effect on measures of adiposity 
in women.  
H2a: This effect will be greater in those consuming full fat products.  
RQ1: Will yogurt consumption be a feasible dietary intervention for improving 
metabolic and adiposity outcomes in women? 
Research Design 
Guided by the ITHBC (Ryan, 2009), an experimental design was utilized to 
address the study objectives. The concepts from the ITHBC were used as a basis to 
develop an intervention related to the prevention or reduction of adiposity and 
improvement of metabolic outcomes in women. The study participants were randomly 
assigned to one of two intervention groups or a control group. The two interventional 
groups received yogurt (i.e., the independent variable) while the control group was asked 
to consume their typical diet during the study, making no alterations to foods typically 
consumed. After 12 weeks, all groups were measured on the same measures of adiposity 
and metabolic markers (i.e., the dependent variables).   
Methods 
Sample. The accessible population for this study was adult women living in north 
Texas. Recruitment was performed at a large obstetrics and gynecology practice as well 
as several other community locations in north Texas. Inclusion criteria included: (a) 
women who were at least 18 years old and (b) those who were able to read, speak, and 
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write English. Exclusion criteria included women with: (a) a diagnosis or currently taking 
medication for diabetes or hyperlipidemia, (b) lactose intolerance, (c) allergy to dairy 
products, (d) those who have had a greater than 20-pound weight change in the past year 
and/or (e) those who were pregnant or were within six weeks after delivery. 
Informed Consent/Human Subjects Protection. Protection of the rights of the 
participants in this project was upheld through a variety of measures implemented to 
ensure safety, privacy, and confidentiality for all of those involved. All procedures were 
evaluated and approved by the IRB at the University of Texas at Tyler. Prior to signing 
the informed consent, full disclosure of the study’s general purpose, benefits, risks, 
participants’ rights, and responsibilities were discussed with all participants. Regulations 
for the Health Insurance Portability and Accountability Act (HIPAA) for protected health 
information was maintained at all times and HIPAA consents were obtained.  
Measures/Instruments. Survey instruments. A researcher-developed Participant 
Demographic Survey was used to collect pertinent patient demographic data. Participants 
provided dietary data about their use of yogurt by completing an 8-item Dairy 
Consumption Questionnaire, Daily Yogurt and Dairy Form, and a Daily Dairy Form). A 
6-item Post Study Feasibility Survey was also used. After development, the researcher 
sent each of these instruments to content experts, colleagues, and others not familiar with 
the research to elicit feedback on the wording and face validity. The forms were 
reorganized and reworded based on feedback.  
Metabolic/Physiologic Outcomes. Ha1 was tested by measuring the effect of the 
yogurt on: blood pressure, fasting serum glucose, insulin, lipid panel (total cholesterol, 
low density lipoprotein [LDL], high density lipoprotein [HDL], and triglycerides), and 
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free cortisol levels. Labs were collected at the contracted laboratory and were prepared, 
stored, and transported according to specific local lab protocols. To reduce bias, a single 
laboratory was utilized for all blood analyses; measurement of blood pressure was 
obtained using the equipment and instruction standards described in the National Health 
and Nutritional Examination Survey (NHANES) Blood Pressure Procedures Manuals 
(Centers for Disease Control, 2009). 
Adiposity outcomes. Ha2 was tested by measuring the effect of the yogurt 
intervention on: body mass index (BMI), waist circumference (cm), hip circumference 
(cm), and body fat percent. Collection of weight and height (to calculate BMI), as well as 
waist and hip circumferences was obtained using the equipment and instruction standards 
described in the National Health and Nutritional Examination Survey (NHANES) 
Anthropometry Manuals (Centers for Disease Control, 2011). The longstanding reputable 
history of NHANES made their manuals an appropriate choice for this study.  
In a recent study of women, Direk and colleagues (2013) found that 
anthropometric measures predicted abdominal fat almost equally as well as Computed 
Tomography (CT) or Dual Energy X-ray Absorptiometry (DXA) scanning. Although CT 
and DXA are considered the gold standard for body fat percent measurement in clinical 
settings, due to funding limitations and access, these tools were not utilized for this study. 
Direk and colleagues’ study (2013) lends support to the use of anthropometric measures 
as estimates of visceral fat. Furthermore, a professional grade bio-impedance scale was 
used to determine body fat composition to assess percentage of body fat. Bio-impedance 
uses electrodes similar to an electrocardiogram (EKG) to run an imperceptible electrical 
current through the body. Lean tissue is a good conductor of electricity while fat tissue is 
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not. The resistance of the flow of the electrical current is measured by an analyzer to 
calculate the body composition. Electrical bio-impendence monitoring has been utilized 
in a number of published studies as an alternative means to CT/DXA to assess total body 
fat percent.  
Compliance and feasibility. The Daily Yogurt and Dairy Form was used to 
provide an answer to RQ1. This format enabled participants to exercise control over some 
of the diet decisions they made as well as promote behaviors of self-regulation, an 
integral concept in the ITHBC model. This form was utilized by participants to track the 
number of ounces, fat (grams), and brand/flavor of yogurt consumed each day. In 
addition, the Post Study Feasibility Survey was administered to assess participants’ 
likelihood to continue the use of yogurt as part of their nutritional intake after the study 
was completed.  
Intervention description. The non-fat intervention group (NF) was asked to 
consume 12 total ounces of non-fat yogurt per day for 12 weeks. Participants were 
allowed to purchase any brand, flavor, or texture of yogurt of their choice. Participant 
were instructed to consume commercial dairy milk yogurt (from cows) that did not 
exceed 160 calories, 18 grams of carbs, or 0 grams of fat (per 6 ounce serving). They 
could consume the yogurt at any time each day in combination with another meal, as a 
meal replacement, or as a snack. They were instructed to record the amount in ounces and 
brand/flavor of yogurt consumed each day. The participants were asked to consume all 
other dairy products in the same amounts and frequencies as before the study keeping 
their habitual diet. They were also asked to record both the yogurt and dairy consumption 
for each day on the Daily Yogurt and Dairy Form.  
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The full-fat intervention group (FF) was asked to consume 12 ounces of full fat 
yogurt per day for 12 weeks. There was no upper limitation on calories, carbs, or fat. 
Participants were instructed to consume yogurt with at least 6 grams of fat per 6 ounce 
serving. They were also asked to record the amount in ounces, grams of fat, and 
brand/flavor of yogurt consumed each day. The participants were asked to consume all 
other dairy products in the same amounts and frequencies as before the study to maintain 
their habitual diet. They were asked to record both the yogurt and dairy consumption for 
each day on the Daily Yogurt and Dairy Form.  
The control group (CG) was asked to make no changes to their current dietary 
habits. They were instructed to document dairy consumption on the Daily Dairy Form. 
Though this could have heightened the awareness of consuming dairy products, with the 
emphasis not on yogurt it was expected that they would not consume more yogurt than 
usual. The form also served as a means to assess typical yogurt intake within the sample.   
Data Collection. Participants were recruited through locally posted community 
flyers and letters to current patients at a large obstetrics and gynecology practice. All 
participants were interviewed in person, via phone, or email (depending on how they 
contacted the PI) to assess for study eligibility. The researcher’s contact information was 
listed for all flyers posted in the community. Staff at the obstetrics and gynecology 
practice was instructed on how to inform prospective participants of the study and next 
steps for contacting the researcher when interested women were identified.  
If inclusion criteria were met, potential participants were asked to meet with the 
PI in an initial session in which the purpose and procedures of the study were disclosed. 
After signing the IRB-approved consent and HIPAA forms, participants were randomly 
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assigned to one of three groups (a control group, a non-fat yogurt group, or a full-fat 
yogurt group) by drawing a sealed envelope.  
After randomization, baseline demographic surveys, anthropometric 
measurements, and lab work were then obtained by the PI and entered into each of the 
participant’s individual file. All data collection was performed in a private room to ensure 
privacy. Following baseline data collection, participants were instructed not to make any 
major diet changes during the course of the 12-week study unless instructed to do so as 
indicated by the group assignment. They were also asked not to change their activities or 
exercise regimens during this time. Participants were instructed to report any new 
medications, changes in medications, or changes in health status. Participants in the full-
fat and non-fat yogurt groups were given a Daily Yogurt and Dairy Form to specifically 
document the amount and type of yogurt consumed each day, as well as other dairy 
products consumed. Participants in the control group completed the Daily Dairy Form to 
document all dairy intake on a daily basis. The PI advised participants to submit forms 
weekly to encourage and assess compliance with the intervention. Electronic submission 
via email was recommended but postage paid options for regular mail were also 
available. Subjects were then sent to the contracted lab to have their blood drawn after the 
initial body assessments.  At the end of the 12-weeks, anthropometric measurements and 
lab work were reassessed. In addition, the Post Study Feasibility Survey was distributed 
to group participants to obtain feedback on the intervention study. All survey data and 
assessment findings were completed on paper and were stored in a locked file in a locked 
office accessible only to the PI. 
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Procedure. All study data were transcribed into a password protected Statistical 
Program for the Social Sciences (SPSS version 20.0) database for analysis.   Data was 
assessed for accuracy, outliers, and missing responses prior to conducting analysis. 
Discrete variables were examined for accuracy. Continuous variable means and standard 
deviations were examined for errors and to assess for outliers. Descriptive statistics were 
calculated for each variable. For continuous variables, range, mean, median, and standard 
deviation were used. For categorical variables, mean, frequency, and contingency tables 
were used. Chi-square tests (for nominal level data) and ANOVA (for continuous level 
data) were used to compare the distribution of the demographics of the three groups at 
baseline. Post hoc analyses were conducted to determine the differences. 
Feasibility (RQ1) was assessed via time required for recruitment, attrition rate, 
Daily Yogurt/Dairy Consumption Form completion, and responses to the Post Study 
Feasibility Survey.  
Results 
Participant Characteristics. A total of 59 healthy adult women aged 18 to 69 
(mean 34.1 SD 12.48) were initially enrolled in this study and 47 completed the research 
study. Table 1 shows the full fat (18), non-fat (14), and control subjects (15) were similar 
overall based on demographics. The participants in the study were primarily white 
(72.9%), had some college education (81.4%) and had some current form of health 
insurance (79.9%). Baseline participant characteristics are summarized in Table 3.  No 
significant differences were found for any demographic variable across the groups. 
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Table 3. Baseline Demographics of Subjects 
Variable Full-Fat (n=18) Non-Fat (n=14) Control (n=15) P 
Value1 
Age 
     18-30 
     31-43 
     43-56 
     57+ 
 
10 (55.6) 
4 (22.2) 
4 (22.2) 
0 
 
6 (42.9) 
5 (35.7) 
3 (21.4) 
0 
 
7 (46.7) 
5 (33.3) 
1 (6.7) 
2 (13%) 
.368 
Marital Status 
     Married 
     Divorced 
     Never Married 
 
8 (44.4) 
3 (16.7) 
7 (38.9) 
 
7 (50.0) 
3 (21.4) 
4 (28.6) 
 
9 (60.0) 
0 (0) 
6 (40.0) 
.453 
Race 
     White 
     Black 
     Asian 
     Other 
 
13 (72.2) 
2 (11.1) 
1 (5.6) 
2 (11.1) 
 
8 (57.1) 
1 (7.1) 
1 (7.1) 
4 (28.6) 
 
12 (80.0) 
3 (20.0) 
0 (0) 
0 (0) 
.300 
Education 
     8th grade 
     High School 
     Some College 
     College Grad 
     Post Grad 
 
2 (11.1) 
3 (16.7) 
6 (33.3) 
7 (38.9) 
0 (0) 
 
0 (0) 
4 (28.6) 
4 (28.6) 
5 (35.7) 
1 (7.1) 
 
1 (6.7) 
1 (6.7) 
3 (20.0) 
8 (53.3) 
2 (13.3) 
.535 
Working Status 
     No 
     Yes 40+ hrs. 
     Yes 30-40 hrs. 
     Yes 20-30 hrs. 
     Yes less 20 hrs. 
 
11 (61.1) 
2 (11.1) 
2 (11.1) 
2 (11.1) 
1 (5.6) 
 
9 (64.3) 
2 (14.3) 
1 (7.1) 
2 (14.3) 
0 (0) 
 
9 (60.0) 
3 (20.0) 
3 (20.0) 
0 (0) 
0 (0) 
.822 
Insurance Status 
     Employer 
     Self-Insured 
     Medicaid 
     Medicare 
     No Insurance 
     Other 
 
11 (61.1) 
3 (16.7) 
0 (0) 
0 (0) 
2 (11.1) 
2 (11.1) 
 
10 (71.4) 
1 (7.1) 
2 (14.3) 
0 (0) 
0 (0) 
1 (7.1) 
 
9 (60.0) 
1 (6.7) 
0 (0) 
1 (6.7) 
4 (26.7) 
0 (0) 
.753 
Exercise 
     Minutes per   
     Week 
 
125.27 ± 25.48 
 
101.78 ± 33.5 
 
145.33 ± 30.45 
 
.607  
1P values were created using the x2 statistic for ordinal level data and mean with SE for continuous variables. 
 
Metabolic Indicators (Ha1). Baseline blood values were compared across all 
groups for Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides), Glucose, Insulin, 
and Cortisol, and indicated no difference in these values at baseline (Table 4).  For each 
of these measures, a change score was computed to determine the change for each 
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participant from baseline to the final measurement. One-way ANOVA was used to 
compare change scores for each measure across groups.  Differences in change scores 
were not statistically significant when comparing groups according to change in: Total 
Cholesterol, F (2,42) = .289, p = .753, LDL Cholesterol, F (2,42) = .287, p = .752, HDL 
Cholesterol, F (2,42) = .621, p = .543, Triglycerides, F (2,42) = .377, p= .688, Cortisol, F 
(2,41) = .635, p = .535|, Insulin, F (2,42) = .615, p = .546|; or Glucose, F (2,42) = .706, p 
= .500. 
Table 4. Baseline Laboratory Values 
Variable Full-Fat (n=18) Non-Fat (n=14) Control (n=15) 
Serum Lipid Panel 
     Total Cholesterol 
     LDL Cholesterol 
     HDL Cholesterol 
     Triglycerides 
 
171.69 ± 4.82  
96.05 ± 5.10  
54.70 ± 3.35  
101.76 ± 10.45  
 
157.92 ± 8.24 
84.78 ± 6.92  
53.48 ± 2.91  
98.14 ± 17.83 
 
181.72 ± 11.37 
105.09 ± 10.48  
59.36 ± 3.45  
87.09 ± 28.93  
Serum Glucose 87.76 ± 1.86 85.92 ± 1.75 87.81 ± 3.89 
Serum Insulin    12.17 ± 2.77 9.78 ± 2.71 8.63 ± 2.54 
Serum Cortisol     12.47 ± 1.32 11.00 ± 1.657 10.81 ± 1.33  
1Values are means ± SE 
 
Anthropometric Measures (Ha2). Baseline and post intervention anthropometric 
measures were compared across all groups for weight, BMI, body fat percent (%), waist 
circumference, hip circumference, and blood pressure. For each of these measures, a 
change score was computed to determine the change for each participant from baseline to 
the final measurement. One-way ANOVA was used to compare change scores for each 
measure across groups.  Differences in change scores were not statistically significant 
when comparing groups according to change in: Weight F, (2, 46) =.918, p=.407, BMI, F 
(2, 46) = .263, Body Fat Percent, F (2, 46) = .977, p=.385, p=770; and Hip 
Circumference, F (2, 46) =.711, p=.497. Waist Circumference showed a significant 
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change, F (2, 46) =14.17, p<.001, over 12 weeks in all three groups but did not differ 
statistically between groups (Table 5). There were statistically significant differences 
when comparing groups according to change in systolic blood pressure, F (2, 46) = 
10.06, p < .001, and diastolic blood pressure, F (2, 46) = 6.85, p = .003. The full fat group 
showed a significantly greater reduction in overall blood pressure over the 12 weeks 
when compared to the non-fat and control groups. 
Table 5. Anthropometric Means at Baseline and at 12 weeks. 
Variable 
(N=47) 
Full Fat 
 
 
Non Fat 
 
 
Control 
 
 
P 
Value 
 Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks  
Weight 200.84 ± 
61.42 
202.34 ± 
64.80 
190.73 ± 
44.78 
179.07 ± 
40.00 
176.15 ± 
53.62 
177.57 ± 
55.67 
.407 
BMI 34.25 ± 
9.21 
34.32 ± 
9.77 
32.77 ± 
9.21 
31.4 ± 
7.08 
29.18 ± 
9.21 
29.67 ±  
8.87 
.385 
Waist 
Circumference 
99.02 ± 
19.66 
94.77 ± 
19.32 
94.97 ± 
13.25 
89.71 ± 
12.64 
88.29 ± 
15.62 
86.20 ± 
15.14 
.231 
Hip 
Circumference 
118.25 ± 
14.41 
118.00 ± 
14.69 
116.72± 
14.84 
111.28 ± 
12.46 
111.64 ± 
15.08 
110.53 ± 
14.87 
.497 
Body Fat % 41.83 ± 
9.05 
41.92 ± 
8.72 
40.6 ± 
8.68 
38.67 ± 
8.47 
37.04± 
10.61 
36.32 ± 
11.52 
.385 
Systolic BP 122.60 ± 
12.08 
117.11 ± 
7.84 
120.90 ± 
11.47 
127.35 ± 
10.66 
118.17± 
12.43 
126.73 ± 
14.09 
.000* 
Diastolic BP 78.70 ± 
8.82 
74.67± 
7.19 
77.27 ± 
7.07 
79.64 ± 
7.12 
77.35 ± 
9.02 
80.33 ± 
10.89 
.003* 
*Denotes Statistically Significant Value 
 
Feasibility. The recruitment of new participants took close to eight months from 
the initial start date. Fifty-nine participants completed all initial surveys, consents and 
initial anthropometric body assessments. However, of the 59 participants, 12 never went 
to the laboratory to have the serum blood markers completed at baseline, thus having 
incomplete files. Of the 12 who did not have the blood work done at baseline, two of 
these subjects did continue the study without the lab work portions completed. The other 
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10 did not finish the study. Forty-seven participants (80%) completed the 12-week study 
with all baseline and post intervention assessments completed.  
Participants in the yogurt groups were instructed to consume 12 ounces of yogurt 
per day (equating to a projected 1008 ounces during the entire 12 weeks if they consumed 
all servings). The actual average yogurt consumption was 665.62 (SD= 268.47) ounces 
for full fat group participants, 652.25 (SD= 258.48) for non-fat group participants and 
23.24 (SD= 26.35) ounces for the documentation group (who were instructed to keep 
their habitual diet). Most participants in the intervention groups indicated they missed 
more than 10 servings of yogurt during the study according to the Post Study Feasibility 
Survey. 
 In addition to ordinal level questioning, the Post Study Feasibility Survey 
contained a response set that offered participants a narrative section to document 
comments or concerns with the yogurt intervention or other aspects of the research study. 
Very few comments were documented by the participants on this portion of the survey. 
However, it should be noted that several participants from the full fat group did voice 
some difficulty in finding full fat yogurt which contained at least 6 grams of fat. Many 
subjects reported that when searching for products utilizing terms such as “traditional,” 
“whole milk,” or simply looking for products that lacked the terms non-fat or low-fat, 
was a challenge. Some stated that even products not claiming to be low fat often times 
had less than 6 grams of fat per serving. Others participants in this group reported they 
could only find full fat whole milk products at health food or organic type stores and that 
their typical grocery store’s selection of full fat yogurts was quite limited. 
 69 
 
Discussion 
Results from this study indicate no statistically significant differences incurred in 
subjects from consuming yogurt as a dietary intervention for measures of adiposity or 
body composition. Since yogurt compliance to the full 12 ounces per day procedure was 
a challenge for many participants, it is possible that a protocol requiring less ounces per 
day (only 1 serving instead of two) over a longer period of time may offer better 
compliance. Interestingly there were also no significant differences in participants who 
consumed full fat verses nonfat products on the outcome measures. Fat sources have 
historically been marketed as detrimental, particularly to those with cardiovascular 
disease and diabetes. However, no statistically significant correlation was seen in the 
biomarkers or body measurements of those consuming full fat, versus non-fat yogurt, 
versus typical diet, over the 12-week intervention. Further investigation of the role of 
dietary intake of fat on common metabolic indicators of cardiovascular disease and 
diabetes is warranted. 
A modest decrease in systolic and diastolic blood pressures of full fat group 
participants was seen. In animal and in vitro studies it has been suggested that bioactive 
substances found in dairy have been shown to have an inhibitory effect on angiotensin 
converting enzyme but further research in human participants is needed (Munn, Sibley, 
Brundage, Ismail, & Earthman, 2013). In a study of 89 adults with hypertension, Drouin-
Chartier et al., (2014) found dairy consumption to have a positive blood pressure 
lowering effect in men with mild to moderate hypertension but found that it may have a 
worsening effect in women.  In a study aimed to examine the longitudinal association of 
dairy consumption with the changes in blood pressure (BP) and the risk of incident 
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hypertension (HTN) among adults, Wang, Fox, Troy, Mckeown, and Jacques (2015) 
utilized 2,636 Framingham Heart Study Offspring Cohort members (1991–2008) to 
investigate such relationships. They found total dairy and total low-fat/fat-free dairy 
intakes were inversely related to changes in diastolic blood pressure. Also, they found 
that each additional serving of yogurt consumed was associated with a 6% (95 % CI 1, 
10) reduced risk of incident hypertension. While there has been support for changes in 
blood pressure associated with yogurt or dairy consumption, there remains a need for 
relevant research to establish a body of evidence further investigating these relationships. 
In terms of feasibility, most participants indicated they would continue to 
consume yogurt after the study but few felt they would eat it daily. In terms of 
sustainability the question of convenience in purchasing full fat products needs further 
scrutiny. Marketing strategies are aimed at low-fat or non-fat products and make up a 
bulk of the products on stores shelves. Further investigations of the differences in full fat 
dairy products and the health benefits or concerns of such must come to light if there will 
be any paradigm shift in the marketing and economics of our food industry. At a 
minimum, if there is no distinguishable difference in the health benefits or harms of full 
fat yogurt compared to non-fat, which would most persons prefer to consume? Artificial 
sweeteners are often utilized in non-fat products to help replace some of the taste lost to 
the reduction of savory fat content. Emerging evidence demonstrating the impact of 
artificial sweeteners on obesity may support the marketability of full-fat yogurt. 
Strengths, Limitations, and Difficulties 
Strengths. The major strength of this study was its experimental design. Many of 
the studies reviewed in the literature were prospective or cross sectional. Very few 
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randomized controlled studies utilizing yogurt have been completed. To our knowledge, 
no experimental studies utilizing yogurt in only women had been done. Utilizing multiple 
measures of adiposity as well as several biomarkers were also strengths in this study. 
Additionally, yogurt is typically inexpensive, and is a widely available dietary 
intervention at most local grocery stores which contributes to sustainability. 
Limitations. As with any longitudinal study, attrition was a limitation. 
Oversampling was done to allow for loss of participants. Utilizing only a few local 
community sites for assessment completion was a limitation for a few participants who 
said they had to drive over 20 minutes to get to the clinic. Woman in the intervention 
groups reported they become tired of consuming 12 ounces of yogurt every day. Very 
few participants were still eating 12 ounces of yogurt towards the end of 12 weeks. There 
were no restrictions made for the brand, flavor, texture or time of day to eat the yogurt, 
but most women stated they were “just tired of eating it every day.”  
The potential for confounding variables, despite exclusion criteria, could not be 
entirely controlled. Since standardization of only a few (not all) nutritional parameters 
was performed, other nutritional co-variables still exist (such as caloric intake). 
Furthermore, actual exercise or energy expenditure was not measured or controlled. 
Participants self-reported exercise (in minutes) at the initial and final assessments with no 
significant differences between groups. Participants were asked not to make any other 
changes in exercise or diet during the study. Although this opened up the possibility of 
confounding variables, it also reflected a real-world approach and helped determine if 
yogurt consumption was feasible without placing additional demands or restrictions on 
participants. Maintaining their previous behaviors mitigated the source and impact of 
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extraneous behaviors since the participants served as their own controls. 
Some variability and human error was possible when obtaining anthropometric 
measurements. Body composition differences, racial and ethnic differences, and clinician 
technique could all have led to discrepancy. Body composition differences and racial and 
ethnic differences were collected in baseline data. Variances in clinician technique was 
addressed by using the same person, equipment, and lab to collect and analyze data to 
help reduce this limitation. The self-reported nature of food consumption was also a 
limitation. Participants may have felt inconvenienced to write in a daily log. This may 
have led to falsification, inaccurate recall, or under-reporting of consumption.  
Challenges. The time it took for recruitment of an adequate number of 
participants was a challenge in this study. Participants were offered free assessments of 
body composition and several metabolic indicators at two time points but some still did 
not seek out these free services. Attrition was also a problem. Two participants reported 
they did not want to eat the yogurt after 1-2 weeks and decided to stop the study, but the 
rest who did not finish were lost to inability to follow up. It should be noted that a 
majority of those who did not follow up were unreachable within the first 2 weeks of the 
study indicating they likely never began the intervention despite enrolling in the study. 
Financially, some women found it to be a burden to purchase full fat yogurt which some 
felt was more difficult to find and often was located at health food or natural/organic type 
stores instead of their typical grocery store which made it more costly. The major 
difficulty in conducting this type of research was the fiscal resources necessary to 
conduct the study. Women could not be asked to pay out of pocket to cover blood work; 
providers could not be expected to provide services for free. In this study, the PI, who is a 
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women’s health nurse practitioner, provided the assessments at no cost. The lab that 
supports the PI’s practice negotiated the lowest cost possible to provide lab services and 
still cover expenses. Intramural funding assisted in covering these study-related expenses. 
Conclusion 
Increased adiposity and declining metabolic health in women results in negative 
consequences to health. The current literature supports the hypothesis of dairy as an 
intervention, but too few interventional studies have been completed. This study helps to 
address the gaps in science that are crucial for this population. Although no known prior 
use in adiposity studies of women, the ITHBC provided a sound theoretical basis to guide 
the research. The National Institutes of Health’s (NIH) Strategic Plan for NIH Obesity 
Research called researchers to develop effective interventions to alleviate the burden of 
obesity (National Institutes of Health, 2011). Promoting healthy weight during critical 
periods and life events is one way NIH proposed to accomplish this. This researcher 
accepted the challenge from NIH, and the findings from this study will contribute to the 
body of knowledge in hopes of improving the health outcomes for women.
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Chapter 5  
Conclusions and Recommendations 
The prevalence of obesity was 36.5% among U.S. adults during 2011–2014 
(CDC, 2015). Flegal, Kit, Orpana, & Graubard (2013) performed a systematic review of 
reported hazard ratios (HRs) of all-cause mortality for overweight and obesity relative to 
normal weight in the general population. They found relative to normal weight, obesity 
was associated with significantly higher all-cause mortality. Obesity concerns as risk 
factors for diabetes and cardiovascular disease have been in the literature for decades. 
Additionally, obesity related morbidity and mortality issues are also a financial burden on 
our already suffering healthcare dollars. A recent meta-analysis found that the “annual 
medical spending attributable to an obese individual was $1,901 ($1,239-$2,582) in 2014 
USD, accounting for $149.4 billion at the national level” (Kim & Basu, 2016). 
The investigation of concerns of the symptoms of perimenopause is just one 
vulnerable group that would benefit from further knowledge of the complex relationships 
between diet and measures of metabolism and adiposity. Findings from the brief review 
of symptoms of the perimenopause demonstrate that increase abdominal fat does play a 
role in the menopause transition, but is poorly understood. Some groups have focused on 
nutrition concerns of this population but again without clear guidelines to direct 
healthcare providers. 
Research stakeholders (NIH Strategic Plan for Obesity, 2011) are actively 
encouraging intervention research studies. Funding opportunities are available for all 
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levels of researchers. 
The general topic of this dissertation was delivering a yogurt intervention for the 
expected benefits in the measures of adiposity and metabolism is an emerging research 
subject. There is conflicting data in the literature regarding dairy consumption, including 
yogurt specifically, as a health intervention. Observational studies are demonstrating 
possible relationships but no clear answer has been ascertained. More specifically the 
benefits for women, and for women at certain life points, is far from clear. Additionally, 
the correlations between the amounts of dairy fat in the products being studied also 
provides a covariate for further scrutiny. The findings from this research project 
demonstrated no acute effect that consuming yogurt had on measures of adiposity but did 
peak further question into the suggestion that certain types of dairy may play a positive 
role on blood pressure. This project also creates further questions as to why no significant 
differences were seen on serum biomarkers with participants consuming full fat versus 
non-fat product, when for decades, fat has been touted as harmful to our metabolic health. 
Understanding these relationships may assist a multitude of health related 
disciplines as they search for better ways to address problems of health and obesity in the 
United States. Nursing, medicine (cardiovascular, endocrine), nutrition, mental health, 
advocates are working tirelessly to seek out answers. Other interest groups such as 
economists, public health activists, farming/dairy corporations, and financial stakeholders 
are also actively involved. The problem of obesity spares no gender, race or ethnicity and 
millions would benefit for further investigation of this research project. 
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Appendix A: Institutional Review Board Approval 
 
 
Office of Research 
and Technology 
Transfer 
Institutional Review 
Board 
 
 
July 28, 2015 
 
Dear Ms. Boyet, 
 
Your request to conduct the study: Effect of a Yogurt Intervention on Adiposity and 
Metabolic Outcomes in Perimenopausal, IRB# SUM2015-105, has been approved by The 
University of Texas at Tyler Institutional Review Board under expedited review. 
This approval includes the written informed consent that is attached to this letter, 
and your assurance of participant knowledge of the following prior to study 
participation: this is a research study; participation is completely voluntary with no 
obligations to continue participating, and with no adverse consequences for non-
participation; and assurance of confidentiality of their data.   
 
In addition, please ensure that any research assistants are knowledgeable about 
research ethics and confidentiality, and any co-investigators have completed human 
protection training within the past three years, and have forwarded their 
certificates to the IRB office (G. Duke).  
Please review the UT Tyler IRB Principal Investigator Responsibilities, and 
acknowledge your understanding of these responsibilities and the following 
through return of this email to the IRB Chair within one week after receipt of 
this approval letter:  
THE UNIVERSITY OF TEXAS AT TYLER 
3900 University Blvd. • Tyler, TX 75799 • 903.565.5774 • FAX: 903.565.5858 
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Appendix A: Institutional Review Board Approval Continued 
 
 This approval is for one year, as of the date of the approval letter 
 The Progress Report form must be completed for projects extending 
past one year. Your protocol will automatically expire on the one year 
anniversary of this letter if a Progress Report is not submitted, per HHS 
Regulations prior to that date (45 CFR 46.108(b) and 109(e): 
http://www.hhs.gov/ohrp/policy/contrev0107.html 
 Prompt reporting to the UT Tyler IRB of any proposed changes to this 
research activity 
 Prompt reporting to the UT Tyler IRB and academic department 
administration will be done of any unanticipated problems involving 
risks to subjects or others 
 Suspension or termination of approval may be done if there is evidence of 
any serious or continuing noncompliance with Federal Regulations or any 
aberrations in original proposal. 
 Any change in proposal procedures must be promptly reported to the IRB 
prior to implementing any changes except when necessary to eliminate 
apparent immediate hazards to the subject.  
 
Best of luck in your research, and do not hesitate to contact me if you need any 
further assistance. 
 
Sincerely, 
 
 
Gloria Duke, PhD, RN 
Chair, UT Tyler IRB 
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Appendix B: Institutional Review Board Modification Approval 
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Appendix C: Recruitment Flyer  
 
 
The University of Texas at Tyler is looking for participants for a clinical nutrition study 
here in north Texas. 
Are you a female over 18?  
Are you interested in being a part of a clinical research study which focuses on weight 
and nutrition? 
We invite you to contact us for more information about this study. 
 
Email: eboyet@patriots.uttyler.edu Phone: 940-891-3600 
The primary investigator for this research study is Eryn Boyet, RN, MSN, WHNP-BC. 
Ms. Boyet is a Women’s Health Nurse Practitioner at Noble Obstetrics & Gynecology. 
She is also nursing faculty at North Central Texas College. You may contact her at the 
above email address for any questions 
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Appendix D: Recruitment Letter 
 
Dear _______________________, 
As a loyal patient of Noble Obstetrics & Gynecology we wanted to let you know about an 
upcoming research study at our office that you may be interested in participating in. One 
of our nurse practitioners, Eryn Boyet, RN, MSN, WHNP-BC, is currently initiating a 
research project for perimenopausal women. This study is done in conjunction with Ms. 
Boyet’s doctoral research (dissertation) at the University of Texas at Tyler. 
The focus of this research study is on nutrition, weight, body fat, and the associated risks 
for cardiovascular disease and diabetes. The research study will involve body 
composition assessments, blood work, dietary evaluations, and the use of a 12 week long 
dietary intervention.  
The study focuses on women who are over 18 years old. The research study will be 
completely voluntary and you may stop at any time. 
If you would like more information about this study or think you may be interested in 
participating, please contact the office below so we can see if you qualify to participate. 
If you would rather, you may also email the researcher directly for more information at 
the email address listed below. 
We look forward to hearing from you! 
Noble Obstetrics Office Phone: 940-891-3600 
Researcher’s Email:  eboyet@patriots.uttyler.edu 
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Appendix E: Informed Consent 
THE UNIVERSITY OF TEXAS AT TYLER 
Informed Consent to Participate in Research 
Institutional Review Board #  
Approval Date:  
1. Project Title: Effect of a Yogurt Intervention on Adiposity and Metabolic Outcomes 
in Women    
2. Principal Investigator: Eryn Boyet, RN, MSN, WHNP-BC 
3. Participant’s Name:  ________________________________________ 
To the Participant:   
You are being asked to take part in this study at The University of Texas at Tyler 
(UT Tyler). This permission form explains: 
 Why this research study is being done.  
 What you will be doing if you take part in the study.  
 Any risks and benefits you can expect if you take part in this study. 
 
After talking with the person who asks you to take part in the study, you should be able 
to: 
 Understand what the study is about.  
 Choose to take part in this study because you understand what will happen 
 
4. Description of Project 
The purpose of this study is to determine the effects that eating certain dairy products has 
on women’s weight, body fat and certain blood tests. The focus of this study involves 
women. Doctors and nurses can use findings from your participation in this study to find 
ways to help women manage their weight and reduce their health risks. 
5. Research Procedures   
If you agree to be in this study, we will ask you to do the following things: 
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Appendix E: Informed Consent Continued 
 
 You will be asked to set up a meeting with the researcher to talk about your diet, 
habits, health status, medication usage, and activity level. 
 You will be asked to record on paper when you eat certain foods during this 
study. You will submit these recordings to the researcher on a weekly basis for 
three months. 
 You may be asked to consume specific types of yogurt during this study. 
 Your height, weight, waist and hip circumference, blood pressure, and body fat 
percent will be measured at the beginning and end of this study. 
 Your blood will be drawn for cholesterol, triglycerides, glucose, insulin, and 
cortisol at the beginning and end of this study. 
 
6. Side Effects/Risks   
Side effects may occur from changing my diet in this study. Minor discomforts such as 
upset stomach, increased gas, or changes in bowel habits may occur from participating in 
this research study. By signing this consent I acknowledge that I do not have any known 
allergies to any dairy products. However, the possibility of an allergic food reaction could 
still occur. If any side effects occur during this study I will notify the researcher right 
away. Injury may result from laboratory phlebotomy procedures necessary for blood 
collection. Although rare, I acknowledge that tissue injury, hemorrhage, and/or infection 
are possible risks. If any injury occurs during this study I will notify the researcher right 
away. 
7. Potential Benefits  
Healthcare providers can help other women by learning about the role of dairy in our 
diets. 
Understanding of Participants 
8.   I have been given a chance to ask any questions about this research study. The 
researcher has answered my questions.  
9.   If I sign this consent form I know it means that: 
 I am taking part in this study because I want to. I chose to take part in this study 
after having been told about the study and how it will affect me. 
 I know that I may choose not be in this study.  If I choose to not take part in the 
study, then nothing will happen to me as a result of my choice. 
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 I know that I have been told that if I choose to be in the study, then I can stop at 
any time. I know that if I do stop being a part of the study, then nothing will 
happen to me. 
 I will be told about any new information that may affect my wanting to continue 
to be part of this study. 
 The study may be changed or stopped at any time by the researcher or by The 
University of Texas at Tyler. 
 The researcher will get my written permission for any changes that may affect 
me. 
 
10.  I have been promised that that my name will not be in any reports about this study 
unless I give my permission.  
11. I also understand that any information collected during this study may be shared as 
long as no identifying information such as my name, address, or other contact 
information is provided). This information can include health information. Information 
may be shared with: 
 Organization giving money to be able to conduct this study. 
 Other researchers interested in putting together your information with information 
from other studies. 
 Information shared through presentations or publications. 
 
12.   I understand The UT Tyler Institutional Review Board (the group that makes sure 
that research is done correctly and that procedures are in place to protect the safety of 
research participants) may look at the research documents. These documents may have 
information that identifies me on them. This is a part of their monitoring procedure. I also 
understand that my personal information will not be shared with anyone.  
13.   I have been told about any possible risks that can happen with my taking part in this 
research project.   
14.   I also understand that I will not be given money for any patents or discoveries that 
may result from my taking part in this research. 
15.   If I have any questions concerning my participation in this project, I will contact the 
principal researcher:  (Eryn Boyet) at (940-224-8167) or email 
(eboyet@patriots.uttyler.edu). 
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16.   If I have any questions concerning my rights as a research subject, I will contact Dr. 
Gloria Duke, Chair of the IRB, at (903) 566-7023, gduke@uttyler.edu, or the 
University’s Office of Sponsored Research:  
The University of Texas at Tyler 
c/o Office of Sponsored Research 
3900 University Blvd 
Tyler, TX  75799 
 
I understand that I may contact Dr. Duke with questions about research-related injuries. 
17. CONSENT/PERMISSION FOR PARTICIPATION IN THIS RESEARCH STUDY 
 
I have read and understood what has been explained to me. I give my permission to take 
part in this study as it is explained to me. I give the study researcher permission to 
register me in this study. I have received a signed copy of this consent form. 
____________________________   _ ___  _ __________     ______________ 
Signature of Participant    Date 
 
_____________________________________  
Witness to Signature  
 
18. I have discussed this project with the participant, using language that is appropriate 
and the participant understands. I believe that I have fully informed this participant of the 
nature of this study and its possible benefits and risks. I believe the participant 
understood this explanation. 
_________________________________ _______________ 
Researcher/Principal Investigator  Date 
IRB approved October 2011; rev 03-26-12 
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Appendix F: HIPAA Consent 
 
The University of Texas at Tyler 
Institutional Review Board 
RESEARCH PARTICIPANT AUTHORIZATION TO USE PROTECTED 
HEALTH INFORMATION 
 
This form is to be signed by research participants in addition to the written 
Informed Consent, or, in the case that a written informed consent is authorized to 
be waived and is not used, this form must be signed anytime that protected health 
information will be used during a research project. 
This does not authorize release of protected health information from any health care 
organization or provider.  
Your records are confidential but may be revealed to appropriate institutional or 
federal authorities. 
There is a federal law (HIPAA), which protects the confidentiality of your health 
information.  This section of the informed consent explains how your health information 
will be used and disclosed for this study and describes your rights, including the right to 
see your health information. Any information collected about you in this study is 
confidential and your name will not be released in any reports or publication without your 
expressed consent. 
By signing this document, you allow the researcher to use your Personal Health 
Information to carry out this Study.  This may include information in your medical 
records such as medical histories, blood samples, x-rays, physical examinations and any 
other data created or collected during the Study. 
By signing this document, you also allow the researcher to release your Health 
Information to the Institutional Review Board (a group at the University that oversees all 
research), the study Sponsor (organization that provides funds for conducting the study) 
and any representatives who work on behalf of Sponsor to conduct the Study.  Other 
persons/investigators directly involved in this study may also receive your Personal 
Health Information. Research data sent to the sponsor or other persons does not include  
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your name, address, or social security number.  Instead, you will be assigned a patient  
identification number.  Your non-identifiable information may also be given to the U.S. 
Food and Drug Administration and other government health agencies around the world 
upon their request. 
The Sponsor may also reanalyze the results of the study at a later date and combine them 
with results of other studies.  While using the information in these ways, the sponsor may 
give it to its affiliated companies in the US or other countries.  The sponsor may also 
share the information with its business partners or companies it hires to provide study-
related services. Again, no identifying information about you will be released at any time 
except by an identification number. 
The information may be given to the FDA or other government health agencies as part of 
applications to gain approval of treatments or to meet other reporting requirements such 
as reporting side effects.  The results of the study may also be presented to other health 
care professionals and published in scientific journals or publications but your identity 
will not be disclosed. 
You have a right to see and make copies of your medical records. 
To ensure the reliability of the Study, however, you agree that you will not be able to see 
or copy your records related to the Study until the Sponsor has completed all work related 
to the Study.  At that time, you may ask to see the Investigator's copy of your medical 
records. 
You may cancel your authorization at any time. 
This authorization to use and disclose your Health Information does not have an 
expiration date.  You may cancel your authorization at any time by sending a written 
notice to the Researcher/Investigator named in this consent at the following address:   
The University of Texas at Tyler 
Institutional Review Board 
c/o Office of Sponsored Research 
3900 University Blvd 
Tyler, TX  75799 
 
If you cancel your authorization, the Investigator will no longer use or disclose your 
Health Information for this Study.  However, we are required to record anything that 
relates to safety of drugs.  I understand the above with regard to my privacy rights. 
__________________________________________ ___________ 
Research Participant Signature    Date 
 
__________________________________________ ___________ 
Witness       Date
 95 
 
Appendix G: Participant Demographic Survey 
 
PARTICIPANT INFORMATION    
 
1. What is today's date?                                                        __________ 
2. What is the zip code where you live?       __________ 
3. What is your age?                                                             __________ 
 
4. Which of the following best describes your race?   (select one item)          
1  American Indian or Alaskan Native 
2  Asian/Oriental or Pacific Islander 
3  Black/African-American 
4  White/Caucasian 
5  Other 
 
5. Are you of Spanish or Hispanic origin or ancestry?  1 Yes  2 No    
 
6. Which of the following best describes your current marital status?   (select one item)           
1 Married 2 Widowed 3 Separated 4 Divorced 5 Never married  
 
7. What is the highest grade you completed in school? (select one item)           
1 8th grade or less  
2 Some high school  
3 High school graduate  
4 Some college  
5 College graduate  
6 Any post-graduate work    
 
8. Which of the following best describes your health insurance status? 
1 Employer sponsored insurance 
2 Self-insured 
3 Medicaid  
4 Medicare 
5 No insurance (self-pay) 
6 Other: _____________________ 
 
9. Are you currently working?   
0  No 
1  Yes - Full Time 40 hours per week or more 
2  Yes - Part Time  30-40 hours per week 
3  Yes - Part Time  20-30 hours per week
             4  Yes - Part Time less than 20 hours per week 
  
10. When was your last menstrual period? 
1 Within the past month 
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2 Within the last three months 
3 Within the last 6 months 
4 Within the last 12 months 
5 It has been over 12 months since I have had a period 
 
11. Which of the following most closely describes your menstrual periods over the past year? 
1 They have a regular pattern, occurring the same time every month (within 6 days) 
2 They are mostly regular but long (>60 days between cycles) 
3 They have an irregular pattern and vary by >7 days each month. 
4 It has been over 12 months since I’ve had a period. 
 
12. How old were you when you had your first menstrual period? _______ 
 
13. How many times have you been pregnant (write “0” if none)? _______ 
 
14. Are you currently pregnant or within 6 weeks of delivery of a baby?  Y     N 
 
15. During the past three months, how many minutes on average did you spend exercising per week?  
 
16. How would you best describe your weight over the past year? 
1 My weight has been stable this year (has not changed by more than 5lbs) 
2 I have gained or lost between 5-10 pounds this past year 
3 I have gained or lost between 11—19 pounds this past year 
4 My weight has changed by over 20 pounds this year 
 
Do you currently have any of the following conditions? (Select one item for each condition)          
 
17. Cardiac disease   1  Yes  2  No 
18. High Cholesterol   1  Yes  2  No 
19. Diabetes    1  Yes  2  No 
20. High blood pressure   1  Yes  2  No 
21. Osteoporosis   1  Yes  2  No 
 
22. Do you smoke?   1  Yes  2  No 
 
Do you currently take any of the following medications? (Select one item for each condition)          
 
23. Estrogen    1  Yes   2  No 
24. Progesterone    1  Yes   2  No 
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25. Testosterone   1  Yes   2  No 
26. Thyroid Medication   1  Yes   2  No 
27. Cholesterol Medication  1  Yes   2  No 
28. Depression/Anxiety Medication 1  Yes   2  No 
 
*If you answered Yes to any of the above medications please list the name of medication(s) in the space below: 
 
 
Do you currently take any of the following supplements? (Select one item for each condition)     
      
29. Calcium Supplement  1  Yes   2  No 
30. Vitamin D Supplement  1  Yes   2  No 
31. Multivitamin Supplement  1  Yes   2  No 
 
32. Are you aware of any ways to reduce abdominal (“belly”) fat in women (other than medications)? 
    1  Yes   2  No 
 
If yes, please list:  
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Appendix H: Dairy Consumption Questionnaire 
Please answer the following questions. Mark one answer for each question. 
1. During the past month, approximately how often did you have any dairy milk? (You may include 
flavored milk but DO NOT include very small amounts of milk used in coffee or meals)
1 Never 
2 1-3 times last month 
3 1-4 times per week 
4 1-2 time per day 
5 More than 3 times per day 
2. During the past month, what kind of milk did you usually drink?
1 Whole fat or regular milk 
2 2% fat or reduced fat milk 
3 1% fat or low-fat milk 
4 Fat free, skim, or nonfat milk 
5 Other/Not sure/I did not drink dairy milk  
3. During the past month, how often did you eat any kind of cheese? (Including cheese used in foods) 
1 Never 
2 1-3 times last month  
3 1-4 time per week 
4 1-2 times per day  
5 More than 3 times per day 
4. During the past month, what kind of cheese did you usually eat?
1 Whole fat or regular cheese 
2 2% fat or reduced fat cheese 
3 Non-fat cheese 
4 Other/Not sure/I did not drink eat cheese  
5. During the past month, how often did you eat any kind of ice cream or frozen dairy product?   
1 Never 
2 1-3 times last month  
3 1-4 time per week 
4 1-2 times per day 
5 More than 3 times per day 
6. During the past month, what kind of ice cream did you usually eat?
1 Regular ice cream 
2 2% fat or reduced fat ice cream 
3 Non-fat ice cream 
4 Other/Not sure/I did not eat dairy ice cream 
7. During the past month, how often did you eat any kind of yogurt?  
1 Never 
2 1-3 times last month  
3 1-4 times per week 
4 1-2 times per day  
5 More than 3 times per day 
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8. During the past month, what kind of yogurt did you usually eat?
1 Regular, whole milk yogurt 
2 2% fat or reduced fat yogurt 
3 Non-fat yogurt 
4 Other/Not sure/I did not drink eat yogurt
  
  
Appendix I: Daily Yogurt and Dairy Consumption Form 
Participant Daily Yogurt Consumption (for Intervention Groups) 
Week 
#___ 
Brand Type 
(Regular, 
Greek, etc…) 
Flavor (Plain, 
Strawberry, 
etc…) 
Total 
Gm of 
Fat 
Total  
Gm 
of 
Protein 
Total 
Ounces 
Eaten 
 
Brand Type 
(Regular, 
Greek, etc…) 
Flavor (Plain, 
Strawberry, 
etc…) 
Total 
Gm of 
Fat 
Total Gm  
of Protein 
Total 
Ounces 
Eaten 
 
Sun Yoplait 
 
Regular Banana 8 gm 5 gm 6 oz. 
 
Dannon Greek Strawb 7 gm 4 gm 6 oz. 
Mon  
 
     
 
      
Tues  
 
     
 
      
Wed  
 
     
 
      
Thurs  
 
     
 
      
Fri  
 
     
 
      
Sat  
 
     
 
      
*Frozen Yogurt is not to be included here. If you consume frozen yogurt please count that on the Non-Yogurt form* 
 
  
  
Appendix I: Daily Yogurt and Dairy Consumption Form Continued 
 
Participant Daily Non-Yogurt Dairy Consumption* (for Intervention Group) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    *If more than three servings of different dairy products are consumed during one day you may use additional sheets of paper. If the same item is used more than once 
per day you may total those servings together.
Week 
#___ 
Type of Dairy 
(Cheese, Milk, 
Ice cream 
etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Type of 
Dairy 
(Cheese, 
Milk, Ice 
cream etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Type of Dairy 
(Cheese, 
Milk, Ice 
cream etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Sun Cheese 
 
5 gm 6 gm 2 oz. Cheese 
 
5 gm 4 gm  Sour Cream 3 gm 5 gm 3 oz. 
Mon  
 
    
 
    
 
   
Tues  
 
    
 
    
 
   
Wed  
 
    
 
    
 
   
Thurs  
 
    
 
    
 
   
Fri  
 
    
 
    
 
   
Sat  
 
    
 
    
 
   
  
  
Appendix J: Daily Dairy Consumption Form 
Participant Daily All-Dairy Consumption* (for Control Group) 
 
 
*If more than three servings of different dairy products are consumed during one day you may use additional sheets of paper. If the same item is used more 
than once per day you may total those servings together.
Week 
#___ 
Type of Dairy 
(Cheese, Milk, 
Ice cream etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Type of 
Dairy 
(Cheese, 
Milk, Ice 
cream etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Type of 
Dairy 
(Cheese, 
Milk, Ice 
cream 
etc…) 
Total 
Gm of 
Fat 
Total Gm 
of Protein 
Total 
Ounces 
Eaten 
 
Sun Cheese 
 
5 gm 6 gm 2 oz. Cheese 
 
5 gm 4 gm 1 oz. Sour 
Cream 
3 gm 5 gm 3 oz. 
Mon  
 
    
 
    
 
   
Tues  
 
    
 
    
 
   
Wed  
 
    
 
    
 
   
Thurs  
 
    
 
    
 
   
Fri  
 
    
 
    
 
   
Sat  
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Appendix K: Post Study Feasibility Survey 
 
PARTICIPANT INFORMATION   What is today's date?      __________ 
 
1. Which study group were you assigned to?    
1 The FULL-FAT dairy group  
2 The NON-FAT dairy group 
3 The dairy DOCUMENTATION ONLY group 
 
For participants who were in the FULL or NON FAT dairy groups please 
answer the following questions. For those in the DOCUMENTATION ONLY 
group skip to question #5.  
 
2. During this study how many times did you FORGET, or chose NOT to consume a 
SERVING of yogurt?    
1 Zero, I consumed every serving  
2 1-3 times 
3 3-6 times 
4 7-10 times 
5 More than 10 times 
 
3. Which statement best describes the most frequent reason why you did not 
consume a yogurt serving?    
1 I forgot  
2 I was not at home 
3 I did not feel well 
4 I did not feel like eating yogurt 
5 Other reason not listed 
6 N/A- I consumed all of the servings 
 
4. After completing the study select which of the following statement best fits you?    
 
1 I will consume yogurt every day 
2 I will consume yogurt 2-3 times per week 
3 I will consume yogurt about once per week 
4 I will rarely consume yogurt 
5 I will never consume yogurt
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Appendix K: Post Study Feasibility Survey Continued 
 
 
 
5. During the past three months, how many minutes on average did you spend 
exercising per week? 
 
 
 
6. Please write any comments that you would like to share with the researcher about 
this study: 
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Biosketch 
NAME: Boyet, Eryn N. (MSN, R.N., WHNP-BC) 
POSITION TITLE: Doctoral Student 
EDUCATION/TRAINING  
INSTITUTION AND LOCATION 
DEGREE 
 
 
Completion 
Date 
MM/YYYY 
 
FIELD OF 
STUDY 
 
Oregon Health & Science University 
Portland, Oregon 
BSN 06/2005 Nursing 
 
Midwestern State University,  
Wichita Falls, Texas 
MSN 08/2010 Nursing Education 
 
University of Texas Health Science 
Center Houston, Texas 
Post-MSN 8/2012 Women’s Health 
Nurse Practitioner 
Certification 
 
University of Texas at Tyler  
Tyler Texas 
 
PhD 
 
12/2016 
 
Nursing 
    
A. Personal Statement 
My program of research is about promoting the health and well-being for women.  For 
my current doctoral work, my specific interest is helping to develop an intervention to 
help women reduce or prevent adiposity and improve their metabolic outcomes. This 
study has set up a program of research for me to further develop the knowledge and 
advocacy for improving the health outcomes for women. During this dissertation, I 
conducted the proposed study with the advisement of my co-committee members, and 
feel I am qualified from my experience in nursing and women’s health to contribute to 
this science. I have counseled countless women in my clinic who are seeking answers to 
improve their health. As a nurse, and personally as a woman, I have observed first-hand 
the physical and emotional challenges patients face related to increase adiposity. The 
multifaceted and lifelong nature of maintaining a healthy weight is exhausting for all 
women. This problem is only compounded with the physiologic changes of the 
menopause transition. As a strong advocate for my patient’s holistic well-being across 
their lifespan, this study is an important step to gain further knowledge on this poorly
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understood and complicated problem. I am excited and determined to help find a safe and 
useful intervention to improve the health for women. 
B. Positions and Honors 
Activity Beginning 
Date 
Ending 
Date 
Related 
To 
Institution 
Medical Missionary 2005 2005 Nursing Christian Medical 
and Dental 
Association 
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College 
Women’s Health Nurse 
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University 
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BSN to DNP Program 
2016 Current Nursing Baylor University 
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2011 Graduate Studies Scholarship--$1500 Midwestern State University 
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2012 Faculty Award of Excellence-University of Texas Health Sciences Center 
Houston 
2013 Innovations in Technology Grant--$2500 North Central Texas College 
2014-16 Buie Presidential Doctoral Scholarship– $3000, University of Texas at Tyler 
 
D. Memberships in Professional Societies 
2013-Current The Honor society of Phi Kappa Phi, University of Texas at Tyler 
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2015-Current Southern Nursing Research Society 
 
E.  Contribution to Science 
Boyet, E. (2014). Current treatment options for the menopausal transition: A brief 
review. Journal of Midwifery & Women’s Health. Under Revision.  
 
 
 
